


### **Earnings Release and Supplemental Report**



**Third Quarter 2022** 



# TABLE OF **Contents**

Earnings Release	3
Consolidated Financial Statements	7
Overview	11
Portfolio Summary	12
Property Count Reconciliations	15
Capitalization	16
Indebtedness	17
Investment Summary	19
Developments and Redevelopments	20
Capital Expenditures	22
Portfolio Diversification	23
Portfolio	
Life Science	24
Medical Office	29
CCRC	35
Other	37
Guidance	38
Glossary and Debt Ratios	39
Company Information	44
Forward-Looking Statements & Risk Factors	46
Discussion and Reconciliation of Non-GAAP Financial Measures	

2

#### **Healthpeak Properties Reports Third Quarter 2022 Results**

DENVER, November 1, 2022 - Healthpeak Properties, Inc. (NYSE: PEAK) today announced results for the third quarter ended September 30, 2022.

#### THIRD QUARTER 2022 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS

- Net income of \$0.65 per share, Nareit FFO of \$0.42 per share, FFO as Adjusted of \$0.43 per share, and blended Total Same-Store Portfolio Cash (Adjusted) NOI growth of 5.1%
  - Life Science and MOB Same-Store Portfolio Cash (Adjusted) NOI growth of 5.4% and 4.9%, respectively
- Increasing full-year 2022 FFO as Adjusted and Total Portfolio Same-Store Cash (Adjusted) NOI growth guidance
- Life science leasing update:
  - Third quarter lease executions totaled over 500,000 square feet
  - \$1 billion active life science development pipeline is 81% pre-leased
- Balance Sheet:
  - Closed on the previously announced \$500 million delayed draw senior unsecured term loans and related interest rate swaps resulting in a 3.5% fixed contractual rate through the initial 2027 maturities
  - Net debt to adjusted EBITDAre and liquidity were 5.3x and \$2.4 billion, respectively, as of September 30, 2022
- Appointed Scott Brinker as President and Chief Executive Officer and elected him to the Healthpeak Board
- The Board of Directors declared a quarterly common stock cash dividend of \$0.30 per share to be paid on November 18, 2022, to stockholders of record as of the close of business on November 7, 2022
- Received the GRESB Green Star designation and named a constituent in the FTSE4Good Index, each for the eleventh consecutive year

#### THIRD QUARTER COMPARISON

	Three Months Ended September 30, 2022			Three Mor Septembe		
(in thousands, except per share amounts)		Amount	Per Share	Amount	I	Per Share
Net income, diluted	\$	353,366	\$ 0.65	\$ 54,442	\$	0.10
Nareit FFO, diluted		227,426	0.42	196,565		0.36
FFO as Adjusted, diluted		235,504	0.43	219,784		0.40
AFFO, diluted		194,963		181,389		

Nareit FFO, FFO as Adjusted, AFFO, Same-Store Cash (Adjusted) NOI and Net Debt to Adjusted EBITDAre are supplemental non-GAAP financial measures that we believe are useful in evaluating the operating performance and financial position of real estate investment trusts (see the "Funds From Operations" and "Adjusted Funds From Operations" sections of this release for additional information). See "September 30, 2022 Discussion and Reconciliation of Non-GAAP Financial Measures" for definitions, discussions of their uses and inherent limitations, and reconciliations to the most directly comparable financial measures calculated and presented in accordance with GAAP in the Investor Relations section of our website at http://ir.healthpeak.com/quarterly-results.

#### SAME-STORE ("SS") OPERATING SUMMARY

The table below outlines the year-over-year three-month SS Cash (Adjusted) NOI growth on an actual and pro forma basis. The Pro Forma table reflects the results excluding government grants under the CARES Act for our CCRC portfolio.

#### Actual

Year-Over-Year Total SS Portfolio Cash (Adjusted) NOI Growth									
	Three M	lonth	Year-To-	Date					
	SS Growth %	% of SS	SS Growth %	% of SS					
Life science	5.4%	49.2%	4.8%	47.8%					
Medical office	4.9%	41.2%	4.3%	40.6%					
CCRC	4.1%	9.6%	5.6%	11.6%					
Total Portfolio	5.1%	100.0%	4.7%	100.0%					

#### **Pro Forma (excluding CARES)**

Year-Over-Year Total SS Portfolio Cash (Adjusted) NOI Growth								
	Three M	onth	Year-To-	Date				
	SS Growth %	% of SS	SS Growth %	% of SS				
Life science	5.4%	49.2%	4.8%	48.3%				
Medical office	4.9%	41.2%	4.3%	41.0%				
CCRC	4.2%	9.6%	(1.8%)	10.7%				
Total Portfolio	5.1%	100.0%	3.9%	100.0%				

#### SOUTH SAN FRANCISCO JOINT VENTURES

#### POINTE GRAND REDEVELOPMENT

As previously announced, in August 2022, Healthpeak and a sovereign wealth fund partner ("SWF Partner") entered into a 70% (Healthpeak) / 30% (SWF Partner) joint venture ("JV") on an approximately 400,000 square foot portfolio of seven life science buildings on Healthpeak's Pointe Grand campus in South San Francisco. The JV generated cash proceeds to Healthpeak of \$126 million at closing.

The JV intends to capitalize on Pointe Grand's A+ location to redevelop the buildings and create differentiated product, offering tenants speed to market in high-quality, purpose-built lab space.

During the third quarter, four buildings entered redevelopment. The remaining three buildings are expected to enter redevelopment as in-place leases expire during 2023.

#### VANTAGE PHASES II & III DEVELOPMENT

As previously announced, Healthpeak and the SWF Partner have also signed agreements to develop Phases II and III of Vantage, a Class A life science development campus that is directly adjacent to Pointe Grand in South San Francisco and currently wholly-owned by Healthpeak. The purchase price for the Vantage Phase II & III joint venture is subject to final entitlements/density, and closing is subject to certain closing conditions, which we expect will be satisfied in the first half of 2023.

#### LIFE SCIENCE LEASING UPDATE

During the third quarter, life science lease executions totaled over 500,000 square feet including:

- 154,000 square foot development lease with a global pharmaceutical company at Vantage in South San Francisco
- 122,000 square foot full-building lease with a mid-cap public biotech company at 333 Oyster Point in South San Francisco
- 55,000 square foot full-building lease at 280 E. Grand on the Pointe Grand redevelopment campus in South San Francisco
- 53,000 square foot lease to a credit tenant at 65 Hayden in Boston

#### **DEVELOPMENT UPDATE**

#### THE SHORE AT SIERRA POINT

During the third quarter, Healthpeak placed in service the remaining 36,000 square feet, representing \$49 million of investment, at Phase II of the The Shore, in Brisbane California.

The Shore is a 23-acre waterfront campus spanning approximately 629,000 square feet and is 100% leased to leading global pharmaceutical and biotech companies.

#### **DISPOSITIONS**

During the third quarter, Healthpeak closed on the sale of two non-core MOB assets, generating proceeds of \$9 million.

#### SHARE REPURCHASE PROGRAM

As previously announced, in August 2022, Healthpeak's Board of Directors approved a share repurchase program authorizing Healthpeak to purchase up to \$500 million of common stock in the open market at Healthpeak's discretion and subject to market conditions, regulatory constraints, and other customary conditions, until August 2024.

In August 2022, Healthpeak repurchased \$56 million of common stock at a weighted average price of \$27.16 per share.

#### **BALANCE SHEET**

In August 2022, Healthpeak closed two previously announced senior unsecured delayed draw term loans (the "Term Loan Facilities") in an aggregate principal amount of up to \$500 million, with initial stated maturities of 4.5 years (plus 1-year extension option at Healthpeak's discretion) and 5 years, and an interest rate of adjusted SOFR plus 85 basis points based on Healthpeak's current credit ratings. Also in August 2022, Healthpeak executed the previously announced forward-starting swaps to fix the interest rate of the Term Loan Facilities at a blended contractual rate of 3.5% for the initial stated term.

In October 2022, Healthpeak drew down the entirety of the \$500 million Term Loan Facilities, which we used to repay commercial paper.

Including net proceeds from the future settlement of shares sold under equity forward contracts during the third quarter of 2021, Net debt to adjusted EBITDAre and liquidity were 5.3x and \$2.4 billion, respectively, as of September 30, 2022.

#### **EXECUTIVE LEADERSHIP ANNOUNCEMENTS**

In October, Healthpeak announced that its Board of Directors had appointed Scott Brinker, the Company's President and Chief Investment Officer, as President and Chief Executive Officer, and elected him to the Healthpeak Board.

Additionally, as previously announced, in October, Scott Bohn, Executive Vice President – Co-Head of Life Science, was appointed Chief Development Officer, in addition to retaining his role as Co-Head of Life Science, and Adam Mabry was promoted to Chief Investment Officer.

In November, Jeffrey Miller was appointed General Counsel. Mr. Miller joined Healthpeak in 2018 and has served in a variety of senior operational leadership roles.

#### **ESG**

Received the GRESB Green Star designation and named a constituent in the FTSE4Good Index, each for the eleventh consecutive year; named a finalist by *IR Magazine* and Corporate Secretary for Best Proxy Statement for the third consecutive year and Best ESG Reporting for the first time; included in *Fortune*'s list of Best Workplaces in Real Estate for the first time.

To learn more about Healthpeak's ESG program and view our 2021 ESG Report, please visit www.healthpeak.com/esg.

#### DIVIDEND

On October 27, 2022, Healthpeak announced that its Board declared a quarterly common stock cash dividend of \$0.30 per share to be paid on November 18, 2022, to stockholders of record as of the close of business on November 7, 2022.

#### **2022 GUIDANCE**

We are updating the following guidance ranges for full year 2022:

- Diluted earnings per common share from \$0.97 \$1.03 to \$0.94 \$0.96
- Diluted Nareit FFO share from \$1.70 \$1.76 to \$1.67 \$1.69
- Diluted FFO as Adjusted per share from \$1.68 \$1.74 to \$1.72 \$1.74
- Total Portfolio Same-Store Cash (Adjusted) NOI growth Guidance from 3.50% 5.00% to 4.50% 5.50%

These estimates do not reflect the potential impact from unannounced future transactions. These estimates are based on our view of existing market conditions, transaction timing, and other assumptions for the year ending December 31, 2022. For additional details and assumptions underlying this guidance, please see page 38 in our corresponding Supplemental Report and the Discussion and Reconciliation of Non-GAAP Financial Measures, both of which are available in the Investor Relations section of our website at http://ir.healthpeak.com.

#### **COMPANY INFORMATION**

Healthpeak has scheduled a conference call and webcast for Wednesday, November 2, 2022, at 9:00 a.m. Mountain Time (11:00 a.m. Eastern Time) to review its financial and operating results for the quarter ended September 30, 2022. The conference call is accessible by dialing (888) 317-6003 (U.S.) or (412) 317-6061 (international). The conference ID number is 4482164. You may also access the conference call via webcast in the Investor Relations section of our website at http://ir.healthpeak.com. An archive of the webcast will be available on Healthpeak's website through November 2, 2023, and a telephonic replay can be accessed through November 8, 2022, by dialing (877) 344-7529 (U.S.) or (412) 317-0088 (international) and entering conference ID number 4571885. Our Supplemental Report for the current period is also available, with this earnings release, in the Investor Relations section of our website.

#### **ABOUT HEALTHPEAK**

Healthpeak Properties, Inc. is a fully integrated real estate investment trust ("REIT") and S&P 500 company. Healthpeak owns and develops high-quality real estate in the three private-pay healthcare asset classes of Life Science, Medical Office and CCRC. At Healthpeak, we pair our deep understanding of the healthcare real estate market with a strong vision for long-term growth. For more information regarding Healthpeak, visit www.healthpeak.com.

#### **FORWARD-LOOKING STATEMENTS**

Statements contained in this release that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements regarding our and our officers' intent, belief or expectation as identified by the use of words such as "may," "will," "project," "expect," "believe," "intend," "anticipate," "seek," "target," "forecast," "plan," "potential," "estimate," "could," "would," "should" and other comparable and derivative terms or the negatives thereof. Examples of forward-looking statements include, among other things: (i) statements regarding timing, outcomes and other details relating to current, pending or contemplated acquisitions, dispositions, transitions, developments, redevelopments, ioint venture transactions, leasing activity and commitments, capital recycling plans, financing activities, or other transactions discussed in this release; (ii) the payment of a guarterly cash dividend; and (iii) the information presented under the heading "2022 Guidance." Pending acquisitions, dispositions, joint venture transactions, leasing activity, and financing activity, including those subject to binding agreements, remain subject to closing conditions and may not be completed within the anticipated timeframes or at all. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could significantly affect our future financial condition and results of operations. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. Further, we cannot guarantee the accuracy of any such forward-looking statement contained in this release, and such forward-looking statements are subject to known and unknown risks and uncertainties that are difficult to predict. These risks and uncertainties include, but are not limited to: epidemics, pandemics or other infectious diseases, including Covid, and health and safety measures intended to reduce their spread, and how quickly and to what extent normal economic and operating conditions can resume within the markets in which we operate: the ability of our existing and future tenants. operators and borrowers to conduct their respective businesses in a manner sufficient to maintain or increase their revenues and manage their expenses in order to generate sufficient income to make rent and loan payments to us and our ability to recover investments made, if applicable, in their operations; increased competition, operating costs and market changes affecting our tenants, operators and borrowers; the financial condition of our tenants, operators and borrowers, including potential bankruptcies and downturns in their businesses, and their legal and regulatory proceedings: our concentration of real estate investments in the healthcare property sector, which makes us more vulnerable to a downturn in a specific sector than if we invested in multiple industries and exposes us to the risks inherent in illiquid investments; our ability to identify and secure replacement tenants and operators and the potential renovation costs and regulatory approvals associated therewith: our property development, redevelopment and tenant improvement activity risks, including project abandonments, project delays and lower profits than expected: changes within the life science industry: high levels of regulation, funding requirements, expense and uncertainty faced by our life science tenants; the ability of the hospitals on whose campuses our MOBs are located and their affiliated healthcare systems to remain competitive or financially viable: our ability to maintain or expand our hospital and health system client relationships; operational risks associated with third party management contracts, including the additional regulation and liabilities of our RIDEA lease structures; economic and other conditions that negatively affect geographic areas from which we recognize a greater percentage of our revenue; uninsured or underinsured losses, which could result in significant losses and/or performance declines by us or our tenants and operators; our investments in joint ventures and unconsolidated entities, including our lack of sole decision making authority and our reliance on our partners' financial condition and continued cooperation: our use of fixed rent escalators, contingent rent provisions and/or rent escalators based on the Consumer Price Index: competition for suitable healthcare properties to grow our investment portfolio; our ability to foreclose on collateral securing our real estate-related loans; our ability to make material acquisitions and successfully integrate them; the potential impact on us and our tenants, operators and borrowers from litigation matters, including rising liability and insurance costs; an increase in our borrowing costs, including due to higher interest rates; the availability of external capital on acceptable terms or at all, including due to rising interest rates, changes in our credit ratings and the value of our common stock, volatility or uncertainty in the capital markets, and other factors; cash available for distribution to stockholders and our ability to make dividend distributions at expected levels; our ability to manage our indebtedness level and covenants in and changes to the terms of such indebtedness; changes in global, national and local economic and other conditions; laws or regulations prohibiting eviction of our tenants; the failure of our tenants, operators and borrowers to comply with federal, state and local laws and regulations, including resident health and safety requirements, as well as licensure, certification and inspection requirements; required regulatory approvals to transfer our senior housing properties: compliance with the Americans with Disabilities Act and fire, safety and other regulations: the regulations: the regulations to, governmental reimbursement programs such as Medicare or Medicaid; legislation to address federal government operations and administration decisions affecting the Centers for Medicare and Medicaid Services; our participation in the CARES Act Provider Relief Fund and other Covid-related stimulus and relief programs: provisions of Maryland law and our charter that could prevent a transaction that may otherwise be in the interest of our stockholders: environmental compliance costs and liabilities associated with our real estate investments: our ability to maintain our qualification as REIT: changes to U.S. federal income tax laws, and potential deferred and contingent tax liabilities from corporate acquisitions; calculating non-REIT tax earnings and profits distributions; ownership limits in our charter that restrict ownership in our stock: the loss or limited availability of our key personnel: our reliance on information technology systems and the potential impact of system failures. disruptions or breaches: and other risks and uncertainties described from time to time in our Securities and Exchange Commission filings. Except as required by law, we do not undertake, and hereby disclaim, any obligation to update any forward-looking statements, which speak only as of the date on which they are made.

#### CONTACT

Andrew Johns, CFA Senior Vice President – Investor Relations 720-428-5400

#### Consolidated Balance Sheets

In thousands, except share and per share data

	Septe	ember 30, 2022	December 31, 2021		
Assets					
Real estate:					
Buildings and improvements	\$	12,633,935	\$	12,025,271	
Development costs and construction in progress		744,711		877,423	
Land		2,647,430		2,603,964	
Accumulated depreciation and amortization		(3,148,019)		(2,839,229	
Net real estate		12,878,057	-	12,667,429	
Net investment in direct financing leases		_		44,706	
Loans receivable, net of reserves of \$5,115 and \$1,813		383,991		415,81	
Investments in and advances to unconsolidated joint ventures		698,903		403,634	
Accounts receivable, net of allowance of \$2,521 and \$1,870		53,964		48,691	
Cash and cash equivalents		112,452		158,287	
Restricted cash		54,500		53,454	
Intangible assets, net		444,215		519,760	
Assets held for sale and discontinued operations, net		51,495		37,190	
Right-of-use asset, net		232,155		233,942	
Other assets, net		752,224		674,615	
Total assets	\$	15,661,956	\$	15,257,519	
Liabilities and Equity	-				
Bank line of credit and commercial paper	\$	1,585,333	\$	1,165,97	
Senior unsecured notes	•	4,657,651	•	4,651,93	
Mortgage debt		347,987		352,08	
		162,874		177,23	
Intangible liabilities, net		12,831		15,050	
Liabilities related to assets held for sale and discontinued operations, net		200,813		204,54	
Lease liability					
Accounts payable, accrued liabilities, and other liabilities		732,895		755,384	
Deferred revenue		835,223		789,207	
Total liabilities		8,535,607		8,111,415	
Commitments and contingencies					
Redeemable noncontrolling interests		127,583		87,344	
Common stock, \$1.00 par value: 750,000,000 shares authorized; 537,533,719 and 539,096,879 shares issued and outstanding		537,534		539,09	
Additional paid-in capital		10,014,707		10,100,29	
Cumulative dividends in excess of earnings		(4,114,806)		(4,120,774	
Accumulated other comprehensive income (loss)		29,526		(3,14)	
Total stockholders' equity		6,466,961	-	6,515,47	
Joint venture partners		330,749		342,23	
Non-managing member unitholders		201,056		201,050	
Total noncontrolling interests		531,805		543,290	
Total equity		6,998,766		7,058,760	
Total liabilities and equity	\$	15,661,956	<b>^</b>	15,257,519	

### **Consolidated Statements of Operations** In thousands, except per share data

	Three Months Ended September 30,		Nine Months Ended September 30,		
	2022	2021	2022	2021	
Revenues:					
Rental and related revenues	\$ 392,301	\$ 353,516	\$ 1,149,530	\$ 1,022,130	
Resident fees and services	122,142	119,022	369,062	352,458	
Income from direct financing leases	-	2,179	1,168	6,522	
Interest income	5,963	6,748	16,950	31,869	
Total revenues	520,406	481,465	1,536,710	1,412,979	
Costs and expenses:					
Interest expense	44,078	35,905	123,531	121,429	
Depreciation and amortization	173,190	177,175	531,412	506,172	
Operating	220,208	202,139	642,499	574,032	
General and administrative	24,549	23,270	73,161	72,260	
Transaction costs	728		1,636	1,417	
Impairments and loan loss reserves (recoveries), net	3,407		3,678	4,458	
Total costs and expenses	466,160	438,774	1,375,917	1,279,768	
Other income (expense):					
Gain (loss) on sales of real estate, net	(4,149	) 14,635	10,047	189,873	
Gain (loss) on debt extinguishments	—	(667)	—	(225,824	
Other income (expense), net	305,678		326,855	5,604	
Total other income (expense), net	301,529	15,638	336,902	(30,347	
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	355,775	58,329	497,695	102,864	
Income tax benefit (expense)	3,834	. 649	3,775	1,404	
Equity income (loss) from unconsolidated joint ventures	(325	i) 2,327	2,141	4,517	
Income (loss) from continuing operations	359,284	61,305	503,611	108,785	
Income (loss) from discontinued operations	(1,298	601	2,011	384,569	
Net income (loss)	357,986	61,906	505,622	493,354	
Noncontrolling interests' share in continuing operations	(4,016	i) (7,195)	(11,701)	(14,036	
Noncontrolling interests' share in discontinued operations	-	_	-	(2,539	
Net income (loss) attributable to Healthpeak Properties, Inc.	353,970	54,711	493,921	476,779	
Participating securities' share in earnings	(604	.) (269)	(2,523)	(3,001	
Net income (loss) applicable to common shares	\$ 353,366	\$ 54,442	\$ 491,398	\$ 473,778	
Basic earnings (loss) per common share:					
Continuing operations	\$ 0.66	\$ 0.10	\$ 0.91	\$ 0.17	
Discontinued operations	0.00	0.00	0.00	0.71	
Net income (loss) applicable to common shares	\$ 0.66	\$ 0.10	\$ 0.91	\$ 0.88	
Diluted earnings (loss) per common share:					
	\$ 0.65	\$ 0.10	\$ 0.91	\$ 0.17	
Discontinued operations	0.00	• •	0.00	0.71	
	\$ 0.65				
Weighted average shares outstanding:	-	+ 0110	-	+ 0100	
Basic	538,417	539,021	539,105	538,879	
Diluted	546.015	,	544.852	539,159	
Director	0.10,010	000,000	011,002	000,100	

#### **Funds From Operations**

In thousands, except per share data

		Three Months Ended September 30,			Nine Months Ended September 30,			
		2022 2021				2022		2021
Net income (loss) applicable to common shares	\$	353,366	\$	54,442	\$	491,398	\$	473,778
Real estate related depreciation and amortization		173,190		177,175		531,412		506,172
Healthpeak's share of real estate related depreciation and amortization from unconsolidated joint ventures		8,704		4,722		19,049		12,044
Noncontrolling interests' share of real estate related depreciation and amortization		(4,464)		(4,849)		(14,487)		(14,599)
Loss (gain) on sales of depreciable real estate, net <sup>(1)</sup>		5,280		(41,393)		(11,408)		(598,531)
Healthpeak's share of loss (gain) on sales of depreciable real estate, net, from unconsolidated joint ventures		239		(1,068)		89		(6,934)
Noncontrolling interests' share of gain (loss) on sales of depreciable real estate, net		_		3,450		12		5,628
Loss (gain) upon change of control, net <sup>(2)</sup>		(311,438)		_		(311,438)		(1,042
Taxes associated with real estate dispositions		197		483		31		2,666
Impairments (recoveries) of depreciable real estate, net		_		1,952		-		5,695
Nareit FFO applicable to common shares		225,074		194,914		704,658		384,877
Distributions on dilutive convertible units and other	2,352 1,651		51 7,055			-		
Diluted Nareit FFO applicable to common shares	\$	227,426	\$	196,565	\$	711,713	\$	384,877
Diluted Nareit FFO per common share	\$	0.42	\$	0.36	\$	1.30	\$	0.71
Neighted average shares outstanding - diluted Nareit FFO		546,015		544,889		546,677		539,159
mpact of adjustments to Nareit FFO:								
Transaction-related items	\$	681	\$	1,259	\$	1,573	\$	6,638
Other impairments (recoveries) and other losses (gains), net <sup>(3)</sup>		2,897		20,073		(5,874)		25,161
Restructuring and severance related charges		_		_		_		2,463
Loss (gain) on debt extinguishments		-		667		-		225,824
Casualty-related charges (recoveries), net <sup>(4)</sup>		4,514		558		4,103		5,203
Casually-related charges (recoveries), her	_	8,092		22,557		(198)		265,289
Fotal adjustments			_				_	050 400
	_	233,166		217,471		704,460		650,166
Total adjustments	_	233,166 2,338		217,471 2,313		704,460 7,055		
Fotal adjustments   FFO as Adjusted applicable to common shares	\$		\$		\$		\$	650,166 6,323 656,489
FO as Adjusted applicable to common shares Distributions on dilutive convertible units and other	\$	2,338	\$ \$	2,313	\$ \$	7,055	\$ \$	6,323

- 1) This amount can be reconciled by combining the balances from the corresponding line of the <u>Consolidated</u> <u>Statements of Operations</u> of this Earnings Release and Supplemental Report and the detailed financial information in the Discontinued Operations Reconciliation section included in the corresponding Discussion and Reconciliation of Non-GAAP Financial Measures, which is available in the Investor Relations section of our website at <u>http://ir.healthpeak.com/</u>.
  - The three and nine months ended September 30, 2022 includes a gain upon change of control related to the sale of a 30% interest to a sovereign wealth fund and deconsolidation of seven previously consolidated life science assets in South San Francisco, California. The gain upon change of control is included in other income (expense), net in the Consolidated Statements of Operations.
- The three months ended September 30, 2022 includes reserves for loan losses recognized in impairments and loan loss reserves (recoveries), net in the Consolidated Statements of Operations. The nine months ended September 30, 2022 also includes the following, which are included in other income (expense), net in the Consolidated Statements of Operations: (i) a \$23 million gain on sale of a hospital that was in a direct financing lease and (ii) \$14 million of expenses incurred for tenant relocation and other costs associated with the demolition of an MOB. The three months ended September 30, 2021 includes the following: (i) a \$22 million goodwill impairment charge in connection with our senior housing triple-net and SHOP asset sales which is reported in income (loss) from discontinued operations in the Consolidated Statements of Operations and (ii) recoveries of loan loss reserves recognized in impairments and loan loss reserves (recoveries), net in the Consolidated Statements of Operations. The nine months ended September 30, 2021 also includes the following: (i) \$6 million of accelerated recognition of a mark-to-market discount, less loan fees, resulting from prepayments on loans receivable which is included in interest income in the Consolidated Statements of Operations and (ii) an additional \$7 million goodwill impairment charge in connection with our senior housing triple-net and SHOP asset sales.
- 4) Casualty-related charges (recoveries), net are recognized in other income (expense), net and equity income (loss) from unconsolidated joint ventures in the Consolidated Statements of Operations. The amounts are reported net of the associated income tax impact.

Adjusted Funds From Operations In thousands

	Three Months Ended September 30,			Nine Months Ended September 30,			ptember 30,
		2022	2021		2022		2021
FFO as Adjusted applicable to common shares	\$	233,166	\$ 217,471	\$	704,460	\$	650,16
Stock-based compensation amortization expense		4,614	4,436		14,635		13,89
Amortization of deferred financing costs		2,691	2,343		8,069		6,67
Straight-line rents		(12,965)	(8,290)		(36,837)		(23,62
AFFO capital expenditures		(24,358)	(28,980)		(75,103)		(72,11
Deferred income taxes		(2,814)	(1,747)		(3,741)		(6,24
Other AFFO adjustments		(7,020)	(5,494)		(20,545)		(15,18
AFFO applicable to common shares		193,314	179,739		590,938		553,57
Distributions on dilutive convertible units and other		1,649	1,650		4,945		4,51
Diluted AFFO applicable to common shares	\$	194,963	\$ 181,389	\$	595,883	\$	558,09
Weighted average shares outstanding - diluted AFFO		544,190	544,889		544,852		544,66

650,166 13,895 6,677 (23,627) (72,112) (6,240) (15,181) 553,578 4,512 558,090 544,660

### The Numbers Overview<sup>(1)</sup>

As of and for the quarter and nine months ended September 30, 2022, dollars, square feet, and shares in thousands, except per share data

	3022	YTD 2022
Financial Metrics		
Diluted earnings per common share	\$0.65	\$0.91
Diluted Nareit FFO per common share	\$0.42	\$1.30
Diluted FFO as Adjusted per common share	\$0.43	\$1.30
Dividends per common share	\$0.30	\$0.90
Portfolio Real Estate Revenues <sup>(2)(3)</sup>	\$527,957	\$1,563,253
Portfolio NOI <sup>(2)(3)</sup>	\$294,639	\$883,239
Portfolio Cash (Adjusted) NOI <sup>(2)(3)</sup>	\$275,416	\$821,809
Portfolio Income <sup>(2)(3)</sup>	\$281,379	\$838,760

	3022 %	of Total SS	YTD 2022	% of Total YTD SS
Same-Store Cash (Adjusted) NOI Growth				
Life science	5.4%	49.2%	4.8%	47.8%
Medical office	4.9%	41.2%	4.3%	40.6%
CCRC <sup>(3)(4)</sup>	4.1%	9.6%	5.6%	11.6%
Total <sup>(4)</sup>	5.1%	100.0%	4.7%	100.0%

	3022		3022
Capitalization		Debt Ratios	
Common stock outstanding and DownREIT units	544,851	Financial Leverage	34.2%
Total Market Equity	\$12,487,985	Secured Debt Ratio	2.0%
Enterprise Debt	\$6,630,747	Net Debt to Adjusted EBITDAre	5.3x
		Adjusted Fixed Charge Coverage	5.3x


	Total P	ortfolio	Operating Portfolio
	Property Count	Capacity <sup>(5)</sup>	Capacity Occupancy <sup>(6)</sup>
Portfolio Statistics			
Life science	149	12,208 Sq. Ft.	10,820 Sq. Ft. 99.0%
Medical office	297	24,076 Sq. Ft.	24,006 Sq. Ft. 90.0%
CCRC	15	7,280 Units	7,280 Units 82.0%
Other <sup>(7)</sup>	19	3,354 Units	3,354 Units 77.5%
Total	480		

- (1) Reconciliations, definitions, and important discussions regarding the usefulness and limitations of the non-GAAP financial measures used in this Supplemental Report can be found in the Glossary herein and the Discussion and Reconciliation of Non-GAAP Financial Measures at <u>https:// ir.healthpeak.com/quarterly-results</u>. The contents of this Earnings Release and Supplemental Report are unaudited and totals may not add due to rounding. Throughout this Supplemental Report, segments, NOI, and other key performance metrics are inclusive of our share in unconsolidated JVs and exclusive of noncontrolling interest share in consolidated JVs. See the Glossary herein and the Discussion and Reconciliation of Non-GAAP Financial Measures for further information, including how pro rata information is derived and the limits of such data.
- (2) Excludes discontinued operations.
- (3) 3Q22 includes \$0.2 million and YTD includes \$7.6 million of government grants under the CARES Act for our CCRC and Other segments, which is included in Other income (expense), net, and Equity income/(loss) from unconsolidated joint ventures, in our Consolidated Statement of Operations; \$0.0 million and \$6.8 million of which relates to properties in Same-Store in our CCRC Segment for 3Q22 and year-to-date, respectively.
- (4) Excluding government grants received under the CARES Act, Same-Store year-over-year three-month Cash (Adjusted) NOI growth would have been 4.2% for CCRC and 5.1% for Total Portfolio, and the year-to-date Same-Store would have been (1.8%) for CCRC and 3.9% for Total Portfolio.
- (5) Total Portfolio Capacity includes estimated capacity upon the completion of Development and Redevelopment projects.
- (6) Occupancy for Life science and Medical office is calculated as of the end of the period presented and is based on square feet. Occupancy for CCRC and Other is calculated based on the most recent three-month average available and is based on units. Occupancy excludes assets held for sale.
- (7) Our Other non-reportable segment includes nineteen assets in our unconsolidated SWF SH JV.

# Portfolio Summary<sup>(1)</sup>

As of and for the quarter ended September 30, 2022, dollars in thousands, excludes discontinued operations

	Property Count	Weighted Average Age <sup>(2)</sup>	Portfolio Investment	Portfolio Income
Property Portfolio				
Life science	135	14	\$ 7,705,134	\$ 139,539
Medical office	289	24	6,120,079	109,678
CCRC	15	31	2,270,573	21,882
Other	19	23	462,219	4,316
	458	20	\$ 16,558,005	\$ 275,416
Developments				
Life science	7	_	\$ 539,096	\$ _
Medical office	1	_	258	_
	8	_	\$ 539,354	\$ _
Redevelopments <sup>(3)</sup>				
Life science	7	_	\$ 375,699	\$ _
Medical office	7	-	31,270	_
CCRC	_	_	2,226	_
	14	_	\$ 409,195	\$ _
Debt Investments				
Seller financing loans	_	_	\$ 358,526	\$ 5,541
Other	_	-	22,666	422
	-	-	\$ 381,192	\$ 5,964
Total				
Life science	149	14	\$ 8,619,929	\$ 139,539
Medical office	297	24	6,151,607	109,678
CCRC	15	31	2,272,800	21,882
Other	19	23	843,411	10,280
	480	20	\$ 17,887,746	\$ 281,379



(1) Excludes discontinued operations. Detailed financial information about discontinued operations are included in the Discussion and Reconciliation of Non-GAAP Financial Measures, which is available in the Investor Relations section of our website at http://ir.healthpeak.com/quarterly-results.

(2) Age is weighted based on current quarter Portfolio Income excluding assets sold or held for sale.

(3) Includes Construction in Process ("CIP") and buildings or portions of buildings placed in Redevelopment. Portfolio Income for Redevelopments is reflected in the Property Portfolio section above.

(4) Our pro rata share information is prepared by applying our actual ownership percentage for the period and is intended to reflect our proportionate economic interest in the financial position and operating results of properties in our portfolio.

# **Quarter NOI Summary**

For the quarter ended September 30, 2022, dollars in thousands, excludes discontinued operations

#### **PORTFOLIO NOI SUMMARY**

	Portfolio NOI					SS Portfolio NOI						
	 rtfolio Real e Revenues		Portfolio Operating Expenses		Portfolio NOI	_		SS Portfolio Real Estate Revenues		SS Portfolio Operating Expenses	SS F	Portfolio NOI
Life science	\$ 210,678	\$	(55,918)	\$	154,760	\$		169,679	\$	(44,944)	\$	124,735
Medical office	176,294		(62,537)		113,756			148,887		(50,727)		98,160
CCRC	122,146		(100,264)		21,882			122,146		(99,914)		22,232
Other	18,839		(14,599)		4,240			_		_		_
	\$ 527,957	\$	(233,318)	\$	294,639	\$	;	440,713	\$	(195,586)	\$	245,127

#### **PORTFOLIO CASH (ADJUSTED) NOI SUMMARY**

		Portfolio Cash (Adjusted) NOI					SS Portfolio Cash (Adjusted) NOI							
	P	ortfolio Cash Real Estate Revenues	P	Portfolio Cash Operating Expenses		Portfolio Cash (Adjusted) NOI		_	SS Portfolio Cash Real æ Revenues		SS Portfolio sh Operating Expenses	Cas	SS Portfolio sh (Adjusted) NOI	
Life science	\$	195,447	\$	(55,908)	\$	139,539		\$	159,202	\$	(44,935)	\$	114,266	
Medical office		171,514		(61,836)		109,678			145,972		(50,112)		95,860	
CCRC		122,146		(100,264)		21,882			122,146		(99,914)		22,232	
Other		18,905		(14,589)		4,316			_		_		_	
	\$	508,013	\$	(232,597)	\$	275,416		\$	427,320	\$	(194,962)	\$	232,358	

#### **THREE-MONTH SS**

			SS % of		Ye	ar-Over-Yea	ar			Sequential	
		% of Total SS based	Segment based on	Occup	bancy	G	rowth	Occup	Occupancy Growth		rowth
	Property Count	on SS Cash (Adjusted) NOI	Cash (Adjusted) NOI	3022	3021	SS NOI	SS Cash (Adjusted) NOI	3022	2022	SS NOI	SS Cash (Adjusted) NOI
Life science	118	49%	82%	98.8%	97.5%	6.1%	5.4%	98.8%	98.8%	(0.1%)	0.3%
Medical office	262	41%	87%	91.2%	91.2%	4.3%	4.9%	91.2%	91.4%	1.7%	1.4%
CCRC	15	10%	100%	82.0%	79.5%	7.8%	4.1% (1)	82.0%	81.1%	(6.3%)	(6.3%) (1)
Total	395	100%	<b>84%</b> <sup>(2)</sup>	)		5.5%	5.1% <sup>(1)</sup>			-%	<b>0.1%</b> <sup>(1)</sup>

(1) Excluding government grants received under the CARES Act, Same-Store year-over-year three-month Cash (Adjusted) NOI growth would have been 4.2% for CCRC and 5.1% for Total Portfolio and Same-Store Sequential three-month Cash (Adjusted) NOI growth would have been (5.5%) for CCRC and 0.2% for Total Portfolio.

(2) Total percent of Segment Portfolio Cash (Adjusted) NOI is inclusive of the Other segment, which is not included in Same-Store.

# Year-To-Date NOI Summary

For the nine months ended September 30, 2022, dollars in thousands, excludes discontinued operations

#### **PORTFOLIO NOI SUMMARY**

			Portfolio NOI		SS Portfolio NOI								
	Р	ortfolio Real Estate Revenues		Portfolio Operating Expenses		Portfolio NOI			Portfolio Real ate Revenues		SS Portfolio Operating Expenses		SS Portfolio NOI
Life science	\$	615,083	\$	(154,481)	\$	460,602		\$	457,818	\$	(112,371)	\$	345,448
Medical office		516,595		(182,300)		334,295			412,639		(138,406)		274,234
CCRC		376,161		(300,429)		75,732			375,828		(299,146)		76,681
Other		55,415		(42,804)		12,611			_		_		_
	\$	1,563,253	\$	(680,013)	\$	883,239		\$	1,246,285	\$	(549,923)	\$	696,363

#### **PORTFOLIO CASH (ADJUSTED) NOI SUMMARY**

		Por	tfolio	Cash (Adjusted	I) NO	1	SS Portfolio Cash (Adjusted) NOI							
	Po	ortfolio Cash Real Estate Revenues	Po	ortfolio Cash Operating Expenses		Portfolio Cash (Adjusted) NOI	(	Casł	SS Portfolio n Real Estate Revenues		SS Portfolio h Operating Expenses		SS Portfolio Cash justed) NOI	
Life science	\$	563,928	\$	(154,303)	\$	409,625	\$		428,893	\$	(112,193)	\$	316,700	
Medical office		503,993		(180,272)		323,721			405,632		(136,717)		268,915	
CCRC		376,161		(300,429)		75,732			375,828		(299,146)		76,681	
Other		55,588		(42,857)		12,731			_		_		_	
	\$	1,499,670	\$	(677,861)	\$	821,809	\$		1,210,353	\$	(548,056)	\$	662,296	

#### **NINE-MONTH SS**

			SS % of		Year-O	ver-Year	
		% of Total SS based on	Segment based on	Occup	ancy	Grov	wth
	Property Count	Cash (Adjusted) NOI	Cash (Adjusted) NOI	2022	2021	SS NOI	SS Cash (Adjusted) NOI
Life science	114	48%	77%	98.8%	97.4%	4.9%	4.8%
Medical office	246	41%	83%	91.3%	91.3%	3.8%	4.3%
CCRC	15	12%	100%	81.3%	79.2%	8.5%	5.6% (1)
Total	375	100%	81% <sup>(2</sup>	2)		4.9%	<b>4.7%</b> <sup>(1)</sup>

(1) Excluding government grants received under the CARES Act, year-to-date Same-Store Cash (Adjusted) NOI growth would have been (1.8%) for CCRC and 3.9% for Total Portfolio.

(2) Total percent of Segment Portfolio Cash NOI is inclusive of the Other segment, which is not included in Same-Store.

### **Property Count Reconciliations**

As of September 30, 2022

#### **PROPERTY COUNT RECONCILIATION**

	Life Science	Medical Office	CCRC	Other	Total
Prior Quarter Total Property Count	149	298	15	19	481
Assets sold	_	(2)	_	_	(2)
New Developments	_	1	_	_	1
Current Quarter Total Property Count	149	297	15	19	480
Acquisitions non-Stabilized	(5)	(13)	_	_	(18)
Assets in Development	(7)	(1)	_	_	(8)
Recently completed Developments	(5)	(10)	_	_	(15)
Assets in Redevelopment	(7)	(7)	_	-	(14)
Recently completed Redevelopments	(4)	(4)	_	-	(8)
Assets held for sale	(2)	_	_	_	(2)
Segment exclusions	_	_	_	(19)	(19)
Significant tenant relocation <sup>(1)</sup>	(1)	_	_	_	(1)
Three-Month SS Property Count	118	262	15	-	395
Acquisitions non-Stabilized	_	(16)	_	_	(16)
Recently completed Developments	(1)	_	_	_	(1)
Significant tenant relocation <sup>(1)</sup>	(3)	_	_	_	(3)
Nine-Month SS Property Count	114	246	15	-	375

#### **SEQUENTIAL SS**

	Life Science	Medical Office	CCRC	Other	Total
Prior Quarter Three-Month SS Property Count	119	247	15	-	381
Acquisitions now Stabilized	_	15	—	—	15
Assets in Redevelopment	(4)	—	-	—	(4)
Prior Development/Redevelopment now Stabilized	1	—	_	_	1
Significant tenant relocation <sup>(1)</sup>	2	—	-	—	2
Current Quarter Three-Month SS Property Count	118	262	15	-	395

(1) Life science assets removed from Same-Store due to significant tenant relocations from buildings that were in Same-Store to buildings that are not in Same-Store, where the relocation results in increased revenues to the Company.

### Capitalization

Dollars and shares in thousands, except price per share data

#### **TOTAL CAPITALIZATION**

		:	September 30, 20	)22	
	Shares		Value		Total Value
Common stock (NYSE: PEAK)	537,534	\$	22.92	\$	12,320,279
Convertible partnership (DownREIT) units	7,317		22.92		167,706
Total Market Equity	544,851			\$	12,487,985
Consolidated Debt					6,590,971
Total Market Equity and Consolidated Debt	544,851			\$	19,078,956
Share of unconsolidated JV debt					39,776
Total Market Equity and Enterprise Debt	544,851			\$	19,118,732

#### **COMMON STOCK AND EQUIVALENTS**

			0	verage Shares September 30	rage Shares Weighted Average Shares September 30, 2022 Nine Months Ended September 30						
	Shares Outstanding September 30, 2022		Diluted Nareit FFO	Diluted FFO as Adjusted	Diluted AFFO	Diluted EPS	Diluted Nareit FFO	Diluted FFO as Adjusted	Diluted AFFO		
Common stock	537,534	538,417	538,417	538,417	538,417	539,105	539,105	539,105	539,105		
Common stock equivalent securities <sup>(1)</sup> :											
Restricted stock units	1,778	281	281	281	281	255	255	255	255		
Convertible partnership (DownREIT) units	7,317	7,317	7,317	7,317	5,492	5,492	7,317	7,317	5,492		
Total common stock and equivalents	546,629	546,015	546,015	546,015	544,190	544,852	546,677	546,677	544,852		

(1) The weighted average shares as of September 30, 2022 represent the current dilutive impact, using the treasury stock method, of 1.8 million restricted stock units and 7.3 million DownREIT units. All 9.1 million shares under ATM forward contracts that had not been settled as of September 30, 2022 were anti-dilutive.

### Indebtedness

As of September 30, 2022, dollars in thousands

#### **DEBT MATURITIES AND SCHEDULED PRINCIPAL REPAYMENTS (AMORTIZATION)**<sup>(1)</sup>

		Senior Unsecu	red Notes	Mortgag	je Debt			S	hare of Unco	onsolidated JV Debt		e Debt
	Bank LOC & Commercial Paper <sup>(2)</sup>	Amounts	Rates %	Amounts	Rates %	С	onsolidated Debt		Amounts <sup>(3)</sup>	Rates %	Amounts	Rates %
2022	\$ -	\$ -	_	\$ 1,289	3.80	\$	1,289	\$	121	2.98	\$ 1,409	3.73
2023	_	_	_	90,089	3.80		90,089		497	2.98	90,586	3.80
2024	_	—	_	7,024	5.49		7,024		38,861	3.80	45,885	4.06
2025	_	800,000	3.93	3,209	3.80		803,209		_	_	803,209	3.93
2026	1,585,333	650,000	3.39	244,523	4.48		2,479,856		_	_	2,479,856	3.51
2027	_	450,000	1.54	366	5.91		450,366		_	_	450,366	1.54
2028	_	500,000	2.36	_	_		500,000		-	_	500,000	2.36
2029	—	650,000	3.65	—	_		650,000		-	_	650,000	3.65
2030	_	750,000	3.14	_	_		750,000		_	_	750,000	3.14
2031	_	600,000	3.10	_	_		600,000		_	_	600,000	3.10
Thereafter	—	300,000	6.91	_	_		300,000		_	_	300,000	6.91
	\$ 1,585,333	\$ 4,700,000		\$ 346,500		\$	6,631,833	\$	39,479		\$ 6,671,311	
Premiums, (discounts), and debt issuance costs, net	_	(42,349)		1,487			(40,862)		297		(40,565)	
	\$ 1,585,333	\$ 4,657,651		\$ 347,987		\$	6,590,971	\$	39,776		\$ 6,630,746	
Weighted average interest rate %	3.41	3.39		4.35			3.44		3.63		3.44	
Weighted average maturity in years	3.3	6.4		3.2			5.5		1.8		5.5	

- (1) In August 2022, the Company closed two new senior unsecured delayed draw term loans (the "Term Loan Facilities") in an aggregate principal amount of up to \$500 million, with initial stated maturities of 4.5 years (plus 1-year extension option at the Company's discretion) and 5 years, and an interest rate of adjusted SOFR plus 85 basis points based on the Company's current credit ratings. The Company also executed forward-starting swaps in August 2022 that fix the interest rate at a blended contractual rate of 3.5%. In October 2022, the entirety of the \$500 million under the Term Loan Facilities was drawn, and proceeds were used to repay commercial paper borrowings.
- (2) The Company has a \$3.0 billion unsecured revolving line of credit facility (the "Revolving Facility") that matures on January 20, 2026 and contains two six-month extension options. It accrues interest at LIBOR plus 75 basis points and incurs an annual facility fee of 15 basis points, based on our current unsecured credit rating. Commercial paper borrowings are backstopped by the Revolving Facility. As such, we calculate the weighted average remaining term of our commercial paper borrowings using the maturity date of the Revolving Facility.
- (3) Reflects pro rata share of mortgage debt in our unconsolidated JVs.

### Indebtedness

#### As of September 30, 2022, dollars in thousands

#### **DEBT STRUCTURE**

				Weighted Average		
		Balance	% of Total	Rates %	Years to Maturity	
Secured	Fixed rate	\$ 371,309	6	4.22	3.1	
	Floating rate	14,669	_	5.92	2.2	
	Combined	\$ 385,978	6	4.29	3.0	
Unsecured	Fixed rate	4,700,000	71	3.39	6.4	
	Floating rate <sup>(1)(2)</sup>	1,585,333	24	3.41	3.3	
	Combined	\$ 6,285,333	94	3.39	5.6	
Total	Fixed rate	5,071,309	76	3.45	6.1	
	Floating rate <sup>(1)(2)</sup>	1,600,002	24	3.42	3.3	
	Combined	\$ 6,671,311	100	3.44	5.5	
	Premiums, (discounts), and debt issuance costs, net	(40,565)				
	Enterprise Debt	\$ 6,630,746				

#### FINANCIAL COVENANTS<sup>(3)</sup>

	Bank Line	of Credit
	Requirement	Actual Compliance
Leverage Ratio	No greater than 60%	35%
Secured Debt Ratio	No greater than 40%	2%
Unsecured Leverage Ratio	No greater than 60%	38%
Fixed Charge Coverage Ratio (12 months)	No less than 1.50x	5.8x
Tangible Net Worth (\$ billions)	No less than \$7.7B	\$10.5B

#### **CREDIT RATINGS (SENIOR UNSECURED DEBT)**

Moody's	Baa1 (Stable)
S&P Global	BBB+ (Stable)
Fitch	BBB+ (Stable)

(1) Includes short term commercial paper borrowings that are backstopped by the Revolving Facility.

(2) In August 2022, the Company closed two new senior unsecured delayed draw term loans (the "Term Loan Facilities") in an aggregate principal amount of up to \$500 million that bear an interest rate of adjusted SOFR plus 85 basis points based on the Company's current credit ratings. The Company also executed forward-starting swaps in August 2022 that fix the interest rate at a blended contractual rate of 3.5%. In October 2022, the entirety of the \$500 million under the Term Loan Facilities was drawn, and proceeds were used to repay commercial paper borrowings. The Company expects to receive proceeds of \$308.5 million related to equity forward contracts, further assumed to be used to repay commercial paper borrowings. Pro forma for these transactions and contemplated repayment, floating rate debt would represent 12% of total debt outstanding.

(3) Calculated based on the definitions contained in the credit agreement, which may differ from similar terms used within the Debt Ratios section of this document.

### Investment Summary

As of and for the nine months ended September 30, 2022, dollars and square feet in thousands

#### **INVESTMENT SUMMARY**

	MSA	Date	Capacity	Property Count	Property Type	Three Months Ended September 30, 2022	Months Ended mber 30, 2022
ACQUISITIONS							
67 Smith Place land parcel	Boston, MA	January	_	_	Life science	\$ –	\$ 72,000
Vista Sorrento land parcel	San Diego, CA	January	-	_	Life science	-	24,000
Webster	Houston, TX	March	95 Sq. Ft.	2	Medical office	_	43,000
Northwest Medical Plaza	Fayetteville, AR	May	68 Sq. Ft.	1	Medical office	-	25,700
OTHER INVESTMENTS							
Development fundings						118,315	298,545
Redevelopment fundings						48,374	92,087
Loan fundings						16	1,502
Total				3		\$ 166,705	\$ 556,834

#### **REAL ESTATE HELD FOR SALE**

Property Type	Capacity	Property Count	Projected Sales Price
Life science	166 Sq. Ft.	2	115,000
Total		2	\$ 115,000

#### **DISPOSITIONS**

	Dete	Gamaaita	Property	Durante Truce	Color Drive	Trailing Cash Yield <sup>(1)</sup>
	Date	Capacity	Count	Property Type	Sales Price	Y leid."
Myriad IV	January	70 Sq. Ft.	1	Life science	\$ 14,250	
Frye Regional Medical Center	February	257 Sq. Ft.	1	Medical office	67,625	
SWG MOB	April	59 Sq. Ft.	1	Medical office	13,750	
Stansbury Health Center	May	22 Sq. Ft.	1	Medical office	5,480	
Fort Worth land parcel	June	N/A	—	Medical office	900	
Kindred Hospital Dallas	June	81 Sq. Ft.	1	Medical office	6,500	
Red Oak MOB	July	53 Sq. Ft.	1	Medical office	1,000	
Westpark Plaza MOB	July	69 Sq. Ft.	1	Medical office	7,500	
South San Francisco Pointe Grand JV <sup>(2)</sup>	August	N/A	N/A	Life science	125,934	
Total			7		\$ 242,939	8.1%

Represents the weighted average yield calculated using Cash (Adjusted) NOI for the twelve month period prior to sale for dispositions.
Sales price of \$125.9 million represents 30% share of the \$419.8 million South San Francisco Pointe Grand portfolio.

### Developments In Process

As of September 30, 2022, dollars and square feet in thousands

#### **DEVELOPMENT PROJECTS IN PROCESS**

Project <sup>(1)</sup>	MSA	Property Count	<b>CIP</b> <sup>(2)</sup>	Cost to Complete <sup>(2)</sup>	Total at Completion	Total Project Capacity (Sq. Ft.)	% of Total Project Leased	Project Start	Initial Occupancy <sup>(3)</sup>
Life Science									
101 CambridgePark Drive	Boston, MA	1 \$	142,455 \$	33,902	\$ 176,357	161	98	3Q20	4022
Nexus on Grand	San Francisco, CA	1	105,018	57,264	162,282	148	100	1Q21	2023
Sorrento Gateway	San Diego, CA	1	66,004	50,765	116,769	163	100	2021	2023
Callan Ridge <sup>(4)</sup>	San Diego, CA	2	75,185	65,109	140,294	185	100	3Q21	3023
Vantage - Phase I <sup>(4)(5)</sup>	San Francisco, CA	2	150,434	287,753	438,187	343	45	4Q21	4023
		7\$	539,096 \$	494,793	\$ 1,033,889	1,000	81		
Medical Office									
Savannah	Savannah, GA	1 \$	258 \$	32,660	\$ 32,918	70	53	3022	2024
		1 \$	258 \$	32,660	\$ 32,918	70	53		
Total		8\$	539,354 \$	527,453	\$ 1,066,807	1,070	79		
Prejected stabilized violds two		,							

Projected stabilized yields typically range from 6.0% - 8.0%

- (1) The final property at the Shore at Sierra Point Phase II completed in 3Q22. Total capacity and Development cost of the project were 298,000 square feet and \$341 million, respectively, including 66,000 square feet / \$68 million placed in service in 4Q21, 36,000 square feet / \$40 million placed in service in 1Q22, 160,000 square feet / \$184 million placed in service in 2Q22 and 36,000 square feet / \$49 million placed in service in 3Q22. During the quarter, The Shore at Sierra Point Phase II generated non-stabilized Portfolio NOI and Portfolio Cash (Adjusted) NOI of \$5.0 and \$4.4 million, respectively.
- (2) Includes lease commissions and tenant improvements incurred to date, and projected lease commissions through Occupancy.
- (3) Initial Occupancy is generally reflective of revenue recognition commencement, which may not coincide with the start of cash rental payments. Cash rental payments generally occur three to six months following Initial Occupancy.
- (4) For multiple building projects, Initial Occupancy is reflective of the first tenant's occupancy date. Initial Occupancy for subsequent buildings can often follow by six to twelve months.
- (5) Amounts in the table above exclude 40,000 square feet related to the amenity building and include \$84 million of construction cost related to the amenity building. We expect tenants to pay rent on their pro rata share of the amenity building based on the total campus' capacity.

### Redevelopments and Land Held for Development

As of September 30, 2022, dollars and square feet in thousands; includes JV projects at share

#### **REDEVELOPMENT PROJECTS IN PROCESS**

				 In	icre	mental Cos	sts			
Project <sup>(1)</sup>	MSA	Property Type	Property Count	CIP <sup>(2)</sup>	С	Cost to complete <sup>(2)</sup>		Total	Project Start	Estimated Completion Date
600 Broadway	Seattle, WA	Medical office	1	\$ 15,202	\$	2,092	\$	17,294	3Q21	4022
Swedish II and III	Denver, CO	Medical office	2	8,229		8,696		16,925	3021	2023
Woodlake	Los Angeles, CA	Medical office	1	5,679		4,642		10,321	4021	1023
2201 Medical Plaza	Nashville, TN	Medical office	1	664		15,839		16,503	2022	4023
Atrium	Nashville, TN	Medical office	1	471		15,315		15,786	2022	4023
One Forest	Dallas, TX	Medical office	1	1,025		13,290		14,315	2022	4023
1150 Veterans	San Francisco, CA	Life science	1	20,254		23,999		44,253	1022	4022
Sierra Point Towers <sup>(3)</sup>	San Francisco, CA	Life science	1	24,957		40,869		65,826	1022	4022 / 1025
65 Hayden	Boston, MA	Life science	1	1,920		10,880		12,800	2022	4022
Pointe Grand <sup>(4)</sup>	San Francisco, CA	Life science	4	1,170		103,817		104,987	3022	3023 - 3024
Village at Gleannloch Farms <sup>(5)</sup>	Houston, TX	CCRC	-	2,226		4,844		7,070	2022	1023
			14	\$ 81,797	\$	244,283	\$	326,080		

Projected stabilized cash-on-cash return on incremental capital invested typically ranges from 9.0% to 12.0%

#### LAND HELD FOR DEVELOPMENT

Project	MSA	Property Type	Gross Site Acreage	Currently Entitled Rentable Sq. Ft./ Units	Original Investment	Incremental Investment <sup>(6)</sup>	Investment to Date
Vantage - Remaining Phases <sup>(7)</sup>	San Francisco, CA	Life science	12	502 Sq. Ft. \$	129,154 \$	5,007 \$	134,161
West Cambridge Alewife <sup>(8)</sup>	Boston, MA	Life science	22	N/A	289,122	9,358	298,480
Vista Sorrento	San Diego, CA	Life science	10	N/A	43,850	1,443	45,293
Remaining <sup>(9)</sup>	Various	Various	27	N/A	108,655	13,791	122,445
			72	\$	570,781 \$	29,599 \$	600,379

Excludes approximately 1 million square feet of adjacent land development opportunities at our life science and medical office campuses, along with significant developable land at our existing CCRC campuses.

- 1) During the quarter, Stone Oak was completed and placed in service.
- (2) Includes lease commissions and tenant improvements incurred to date, and projected lease commissions through Occupancy.
- (3) Includes a two phase redevelopment with Phase I expected to complete 4022 and Phase II in 1025.
- (4) Includes four of seven buildings that are part of our newly formed JV in our Pointe Grand campus. The remaining buildings are expected to enter redevelopment in 2023.
- (5) The Village at Gleannloch Farms redevelopment (VGF) represents the construction of 12 cottages as part of densification of our adjacent land within our existing VGF campus.
- (6) Includes capitalized interest, entitlement and pre-construction costs.
- (7) With revised zoning, we expect to entitle the balance of our Vantage project for upwards of 1.3 million square feet.
- (8) Excludes 15 acres and \$336 million, which are currently included in our operating portfolio and may be densified in the future.
- (9) Includes 8 acres as part of our Atlantic Health acquisition, 9 acres as part of the Needham land parcel JV at our 37.5% share, and 9 acres as part of our Towers at Sierra Point land parcel.

# Capital Expenditures<sup>(1)(2)</sup>

For the three and nine months ended September 30, 2022, dollars in thousands, except per unit/square foot, excludes discontinued operations

THIRD QUARTER		Life Science	Medical Office	CCRC	Other	Total
Portfolio at share						
Recurring capital expenditures	\$	3,172	\$ 3,409	\$ 4,417 \$	1,098 \$	12,096
Tenant improvements - 2nd generation		1,805	4,139	_	_	5,943
Lease commissions - 2nd generation		1,894	3,871	_	_	5,765
AFFO capital expenditures <sup>(3)</sup>	\$	6,870	\$ 11,418	\$ 4,417 \$	1,098 \$	23,804
Revenue enhancing capital expenditures		4,600	22,933	10,517	983	39,033
Casualty related capital expenditures		_	_	_	486	486
Initial Capital Expenditures ("ICE")		_	1,720	_	_	1,720
Development <sup>(4)</sup>		117,730	585	_	_	118,315
Redevelopment <sup>(4)</sup>		32,367	14,607	1,401	_	48,374
Capitalized interest		10,349	550	12	_	10,911
Total capital expenditures	\$	171,916	\$ 51,813	\$ 16,347 \$	2,568 \$	242,644
Recurring capital expenditures per unit/sq. ft.	ç	\$0.29 per Sq. Ft.	\$0.15 per Sq. Ft.	\$614 per Unit	\$612 per Unit	

YTD					
Portfolio at share					
Recurring capital expenditures	\$ 5,459	\$ 9,123	\$ 10,352	\$ 2,621 \$	\$ 27,554
Tenant improvements - 2nd generation	9,681	21,485	_	_	31,167
Lease commissions - 2nd generation	5,219	8,778	_	_	13,996
AFFO capital expenditures <sup>(3)</sup>	\$ 20,359	\$ 39,386	\$ 10,352	\$ 2,621 \$	\$ 72,717
Revenue enhancing capital expenditures	22,300	51,786	26,790	2,424	103,300
Casualty related capital expenditures	-	—	_	1,034	1,034
Initial Capital Expenditures ("ICE")	_	5,484	_	_	5,484
Development <sup>(4)</sup>	293,204	5,342	_	_	298,545
Redevelopment <sup>(4)</sup>	49,081	40,797	2,209	_	92,087
Capitalized interest	25,935	1,606	17	_	27,559
Total capital expenditures	\$ 410,879	\$ 144,401	\$ 39,368	\$ 6,078 \$	\$ 600,726
Recurring capital expenditures per unit/sq. ft.	\$ 0.50 per Sq. Ft.	\$0.41 per Sq. Ft.	\$1,420 per Unit	\$1,460 per Unit	
				-	

(1) Excludes corporate capitalized expenses such as IT systems, furniture, fixtures and equipment at corporate or satellite offices, etc.

(2) A reconciliation to our Consolidated Statement of Cash Flows can be found in the Discussion and Reconciliation of Non-GAAP Financial Measures document located at <a href="https://ir.healthpeak.com/quarterly-results">https://ir.healthpeak.com/quarterly-results</a>.

(3) Includes AFFO capital expenditures on unconsolidated JVs for the quarter of \$1.4 million and \$3.1 million year-to-date. Excludes noncontrolling interest share of AFFO capital expenditures on consolidated joint ventures for the quarter of \$0.6 million and \$1.4 million year-to-date, which are included in the Other AFFO adjustments line item of the Adjusted Funds From Operations reconciliation.

(4) Development and Redevelopment include related tenant improvements and lease commissions.

### **Portfolio Diversification**

As of and for the quarter ended September 30, 2022, dollars in thousands, excludes discontinued operations

#### **PORTFOLIO INCOME BY MSA**

MSA	Property Count <sup>(1)</sup>	Life Science	Medical Office	CCRC	Other	Total	% of Total
San Francisco, CA	82 \$	85,333 \$	795 \$	- \$	- \$	86,128	31
Boston, MA	20	30,064	712	_	_	30,776	11
San Diego, CA	38	21,267	668	_	_	21,935	8
Dallas, TX	35	-	20,961	_	235	21,195	8
Houston, TX	40	_	8,738	1,336	2,514	12,587	4
Philadelphia, PA	6	-	4,824	4,173	_	8,996	3
Tampa, FL	7	_	651	7,134	_	7,785	3
Seattle, WA	7	-	6,971	_	_	6,971	2
Nashville, TN	17	_	6,712	_	_	6,712	2
Denver, CO	20	_	5,482	_	502	5,984	2
Louisville, KY	11	_	4,878	_	_	4,878	2
Remaining	189	2,875	48,286	9,239	1,066	61,467	22
Portfolio Cash (Adjusted) NOI	472 \$	139,539 \$	109,678 \$	21,882 \$	4,316 \$	275,416	98
Interest income	_	_	_	_	5,964	5,964	2
Portfolio Income	472 \$	139,539 \$	109,678 \$	21,882 \$	10,280 \$	281,379	100

As of and for the quarter ended September 30, 2022, dollars and square feet in thousands

#### INVESTMENTS<sup>(1)(2)</sup>

MSA	Property Count	Portfolio Investment	Ро	rtfolio Cash (Adjusted) NOI	Total Square Feet	Occupancy %	Annualized Base Rent %
San Francisco, CA	81	\$ 4,052,861	\$	85,333	5,361	99.0	60.3
Boston, MA	19	2,222,859		30,064	2,474	98.8	21.5
San Diego, CA	36	1,297,534		21,267	2,579	98.9	17.0
Remaining	6	131,880		2,875	406	100.0	1.2
	142	\$7,705,134	\$	139,539	10,820	99.0	100.0

#### SAME-STORE

	3021	4021		1022		2022	3022
Property Count	118	118		118		118	118
Portfolio Investment	\$ 6,248,127	\$ 6,261,355	\$	6,228,313	\$	6,242,357	\$ 6,383,283
Square Feet	8,981	8,981		8,981		8,981	9,039
Occupancy %	97.5	96.7		98.5		98.8	98.8
Portfolio Real Estate Revenues	\$ 156,521	\$ 154,550	\$	160,190	\$	164,967	\$ 169,679
Portfolio Operating Expenses	(38,924)	(37,062)		(39,431)		(40,158)	(44,944)
Portfolio NOI	\$ 117,597	\$ 117,488	\$	120,759	\$	124,809	\$ 124,735
Portfolio Cash Real Estate Revenues	\$ 147,371	\$ 146,017	\$	150,441	\$	154,084	\$ 159,202
Portfolio Cash Operating Expenses	(38,914)	(37,053)		(39,271)		(40,149)	(44,935)
Portfolio Cash (Adjusted) NOI	\$ 108,456	\$ 108,964	\$	111,170	\$	113,935	\$ 114,266
Portfolio Cash (Adjusted) NOI Margin %	73.6	74.6		73.9		73.9	71.8
Pro Forma Portfolio Cash (Adjusted) NOI Margin $\%^{(3)}$	96.3	96.2		96.2		96.4	95.5
		Year-Ove	r-Yea	ar Three-Mon	th SS	6 Growth %	5.4%

(1) Properties that are held for sale are included in property count, Investment, Cash (Adjusted) NOI, and square feet but are excluded from Occupancy.


(2) Excludes seven properties that are in Development.

(3) Approximately 90% of operating expenses reported above are recoverable from tenants and are reported gross in both Portfolio Cash Real Estate Revenues and Portfolio Cash Operating Expenses. Pro Forma Portfolio Cash (Adjusted) NOI Margin % has been adjusted to remove recoverable expenses from both revenue and expenses.

As of September 30, 2022, dollars and square feet in thousands

#### **TENANT CONCENTRATION**<sup>(1)</sup>

		Weighted Average	Leased Fe		Annualized Base Rent <sup>(2)</sup>		
Parent Name	Market Cap (in millions)	Remaining Lease Term in Years	Amount	% of Total	Amount	% of Total	
Amgen	\$ 120,573	1.9	624	6	\$ 50,811	9	
Johnson & Johnson	429,503	6.2	349	3	19,702	3	
Bristol-Myers Squibb	151,795	7.0	242	2	16,032	3	
Arcus Biosciences	1,888	9.3	246	2	13,845	2	
Pfizer <sup>(3)</sup>	245,597	7.1	180	2	13,239	2	
Nkarta	640	10.6	130	1	11,669	2	
AstraZeneca <sup>(4)</sup>	173,322	4.3	180	2	11,363	2	
General Atomics	Private	7.0	702	7	10,954	2	
Denali Therapeutics	3,786	6.6	148	1	10,817	2	
Rigel <sup>(5)</sup>	204	0.3	147	1	10,519	2	
Myriad Genetics	1,539	3.4	288	3	9,827	2	
Sorrento Therapeutics	695	16.3	211	2	9,605	2	
Allogene Therapeutics	1,553	9.5	131	1	9,288	2	
Nuvasive	2,281	12.4	252	2	8,965	2	
Fog Pharmaceuticals	Private	8.4	122	1	8,505	1	
Pacira	2,437	7.7	174	2	8,501	1	
Adverum <sup>(6)</sup>	94	9.3	120	1	7,842	1	
Astellas Pharma	24,130	3.1	136	1	7,753	1	
ElevateBio	Private	7.4	142	1	7,644	1	
Takeda	40,369	6.1	184	2	7,514	1	
Remaining		6.7	5,813	55	317,441	56	
		6.7	10,520	100	\$571,835	100	



#### PEAK publicly-traded biotech classification criteria:

Large Cap: market cap > \$10B Mid Cap: market cap between \$10B and \$500M

Small Cap: market cap < \$500M

(1) Excludes two assets held for sale at September 30, 2022.

(2) Annualized Base Rent does not include expense recoveries, additional rent in excess of floors, and non-cash revenue adjustments.

- (3) Includes 164,000 square feet with Global Blood Therapeutics, which was acquired by Pfizer in October 2022.
- (4) Includes 24,000 square feet with LogicBio Therapeutics, which AstraZeneca is under contract to acquire.
- (5) Rigel lease expires in January 2023 and has been 100% re-leased to a large cap credit tenant.
- (6) Adverum has a cash balance of \$235.8 million as of June 30, 2022.

As of September 30, 2022, dollars and square feet in thousands

#### LEASE EXPIRATION DATA<sup>(1)</sup>

			Total		San	Francisco	В	loston	Sa	n Diego	Re	maining
Year	Leased Square Feet	%	Annualized Base Rent <sup>(2)</sup>	%	Leased Square Feet	Annualized Base Rent <sup>(2)</sup>						
2022(3)(4)	203	2	\$ 11,581	2	200	\$ 11,579	_	\$ -	2	\$ 2	_	\$ -
2023(4)	497	5	27,245	5	285	17,600	22	779	189	8,866	_	_
2024(4)	461	4	30,584	5	430	28,862	_	_	32	1,722	_	_
2025	1,185	11	52,698	9	474	26,854	105	5,384	521	17,304	85	3,157
2026	541	5	22,934	4	310	17,377	24	1,092	207	4,465	_	_
2027	1,561	15	72,659	13	669	43,603	509	15,485	229	9,948	154	3,623
2028	689	7	36,525	6	177	11,697	507	24,546	5	283	_	_
2029	851	8	52,246	9	544	34,245	307	18,001	_	_	_	_
2030	1,198	11	79,453	14	678	47,885	345	23,067	174	8,501	_	_
2031	1,415	13	77,111	13	748	45,642	313	21,881	354	9,588	_	_
Thereafter	1,919	18	108,796	19	792	59,444	291	12,837	836	36,515	—	_
	10,520	100	\$ 571,835	100	5,308	\$ 344,789	2,422	\$ 123,072	2,550	\$ 97,194	240	\$ 6,780

(1) Excludes two assets held for sale at September 30, 2022.

(2) Annualized Base Rent does not include expense recoveries, additional rent in excess of floors, and non-cash revenue adjustments.

(3) Includes month-to-month and holdover leases.

(4) Leased square feet for 2022, 2023, and 2024 includes 172,000, 201,000, and 189,000, respectively, related to the Oyster Point and Pointe Grand campuses, which are planned to undergo Redevelopment. The table excludes 232,000 square feet for four properties in the Pointe Grand campus that are currently in Redevelopment.



As of September 30, 2022, dollars and square feet in thousands, presented at 100%

#### **3022 LEASING ACTIVITY**

	Leased Square Feet	В	nualized ase Rent er Sq. Ft.	% Change in Cash Rents	Tenant provements per Sq. Ft. <sup>(1)</sup>	Leasing C per Sq.		Average Lease Term (Months)	Trailing Twelve Month Retention Rate
Leased Square Feet as of June 30, 2022	10,580	\$	53.72						
Developments placed in service	36		83.40						
Redevelopments placed in service	88		91.80						
Properties placed in (re)development	(221)		54.08						
Expirations	(77)		66.42						
Renewals	51		96.34	30.5	\$ 0.10	\$	0.69	25	64.2%
New leases	181		60.18		4.47		1.99	51	
Terminations	(118)		62.58						
Leased Square Feet as of September 30, 2022	10,520	\$	54.36						

#### YEAR-TO-DATE LEASING ACTIVITY

	Leased Square Feet	B	inualized ase Rent er Sq. Ft.	% Change in Cash Rents	Tenant provements per Sq. Ft. <sup>(1)</sup>	Leasing Costs per Sq. Ft. <sup>(1</sup>		Trailing Twelve Month Retention Rate
Leased Square Feet as of December 31, 2021	10,257	\$	51.45					
Assets Held for Sale	(166)		33.84					
Developments placed in service	458		67.73					
Redevelopments placed in service	163		79.42					
Properties placed into (re)development	(409)		57.20					
Expirations	(344)		67.34					
Renewals	163		95.06	29.0	\$ 0.03	\$ 1.66	39	64.2%
New leases	577		65.82		6.62	2.41	93	
Terminations	(179)		62.58					
Leased Square Feet as of September 30, 2022	10,520	\$	54.36					

As of and for the quarter ended September 30, 2022, dollars and square feet in thousands

#### LEASE TYPE

	 Annualized Base Rent										
	San Francisco	Boston	San Diego	Remaining	Total	% of Total					
Triple-Net <sup>(1)</sup>	\$ 322,570 \$	105,713 \$	92,238 \$	6,780 \$	527,301	92.2					
Base Year <sup>(2)</sup>	21,607	17,224	3,851	—	42,682	7.5					
Gross <sup>(3)</sup>	612	135	1,106	_	1,853	0.3					
Total	\$ 344,789 \$	123,072 \$	97,194 \$	6,780 \$	571,835	100.0					

#### **OWNERSHIP TYPE**

			Total Square Fee	ət			
	San Francisco	Boston	San Diego	Remaining	Total	% of Total	Weighted Average Remaining Lease Term
Ground Lease	_	20	_	240	260	2.4	30 (4)
Fee Simple	5,361	2,454	2,579	166	10,560	97.6	
Total	5,361	2,474	2,579	406	10,820	100.0	

.. . .

\_

#### **CONTRACTUAL LEASE ESCALATORS**

	nnualized Base Rent	% of Annualized Base Rent	Escalator %	
ixed	\$ 565,055	98.8	3.2	
PI	6,780	1.2	8.3	(5)
otal	\$ 571,835	100.0	3.3	

(1) Includes net lease structures, where the tenant is responsible for 100% of their pro rata share of operating expenses.

(2) A lease structure in which the rental rate includes the tenant's pro rata share of operating expenses. The pro rata share of expenses in the first year of the lease is considered the "base year" and any increase in expenses beyond the "base year" is recoverable from the tenant.

(3) A lease structure in which the tenant's pro rata share of operating expenses is presumed to be included in the rental rate, with no variability for fluctuations in operating expenses.

(4) Includes renewal options.

(5) Includes both pure CPI leases and leases with a CPI floor averaging 2%. The CPI escalator presented above is based on the average year-to-date year-over-year change in CPI, which will vary over time and is based on specific lease terms.

As of and for the quarter ended September 30, 2022, dollars and square feet in thousands

#### PORTFOLIO BY MARKET<sup>(1)</sup>

					Multi-tenantSingle-tenantMulti-tenantSingle-tenantMulti-tenantSingle-t								
					On-ca	ampus	Off-ca	mpus <sup>(2)</sup>	Тс	otal			
MSA	Property Count	Portfolio Investment	Portfolio Cash (Adjusted) NOI	Occupancy %	Multi-tenant	Single-tenant	Multi-tenant	Single-tenant	Multi-tenant	Single-tenant	% of Total		
Dallas, TX	33	\$ 875,167	\$ 20,961	92.3	2,067	1,459	209	54	2,276	1,513	16		
Houston, TX	32	511,310	8,738	84.8	1,660	1,421	236	_	1,897	1,421	14		
Seattle, WA	7	286,766	6,971	96.6	674	39	_	_	674		3		
Nashville, TN	17	297,574	6,712	85.3	1,512	10	119	_	1,631	10	7		
Denver, CO	16	347,453	5,482	82.8	1,079	_	35	_	1,114	_	5		
Louisville, KY	11	241,115	4,878	95.7	668	17	447	_	1,115	17	5		
Philadelphia, PA	4	434,958	4,824	77.4	694	_	436	144	1,129	144	5		
Phoenix, AZ	13	235,236	4,169	92.1	519	70	281	_	800	70	4		
Miami, FL	11	145,884	2,956	88.8	543	_	_	30	543	30	2		
Salt Lake City, UT	10	125,279	2,645	90.6	434	_	130	7	564	7	2		
Kansas City, MO	6	126,581	2,591	90.9	351	89	_	8	351	97	2		
New York, NY	3	165,984	2,300	100.0	—	—	139	397	139	397	2		
Greenville, SC	14	156,819	2,160	100.0	232	560	-	51	232	611	4		
Minneapolis, MN	5	125,729	1,735	92.2	228	—	—	81	228	81	1		
Indianapolis, IN	5	119,416	1,531	94.8	214	46	39	-	253	46	1		
Ogden, UT	8	87,272	1,512	86.6	338	—	—	60	338	60	2		
Washington, DC	4	99,586	1,509	81.1	55	29	186	_	242	29	1		
Fresno, CA	1	59,689	1,344	100.0	_	56	_	_	_	56	_		
Colorado Springs, CO	2	34,038	1,200	100.0	118	79	_	_	118	79	1		
Los Angeles, CA	4	83,278	1,131	86.6	161	_	66	_	227	_	1		
Remaining	90	1,560,946	24,330	92.4	2,677	1,398	636	716	3,313	2,114	23		
	296	\$ 6,120,079	\$ 109,678	90.0	14,224	5,273	2,961	1,547	17,185	6,821	100		

(1) Excludes one property that is in Development.

(2) Includes medical office buildings that are off-campus, adjacent (within 0.25 miles of a hospital campus) and anchored (the asset is off-campus, but is 1/3 or more leased to a health system or large physician group).

### Medical Office Same-Store

As of and for the quarter ended September 30, 2022, dollars and square feet in thousands

#### **SAME-STORE**

		3021	4021	1022	2022	3022
Property Count		262	262	262	262	262
Portfolio Investment	\$	4,991,737 \$	5,031,055	\$ 5,057,280 \$	5,084,817 \$	5,119,960
Square Feet		20,971	20,971	20,966	20,973	20,978
Occupancy %		91.2	91.5	91.6	91.4	91.2
Portfolio Real Estate Revenues	\$	141,919 \$	141,965	\$ 144,649 \$	145,654 \$	148,887
Portfolio Operating Expenses		(47,832)	(47,969)	(48,476)	(49,150)	(50,727)
Portfolio NOI	\$	94,087 \$	93,996	\$ 96,173 \$	96,504 \$	98,160
Portfolio Cash Real Estate Revenues	\$	138,541 \$	138,902	\$ 141,733 \$	143,036 \$	145,972
Portfolio Cash Operating Expenses		(47,171)	(47,343)	(47,856)	(48,530)	(50,112)
Portfolio Cash (Adjusted) NOI	\$	91,370 \$	91,559	\$ 93,877 \$	94,506 \$	95,860
Portfolio Cash (Adjusted) NOI Margin %		66.0	65.9	66.2	66.1	65.7
Pro Forma Portfolio Cash (Adjusted) NOI Margin % <sup>(1)</sup>		78.6	78.9	79.1	79.6	79.3
		Y	ear-Over-Yea	r Three-Month S	S Growth %	4.9%

(1) Approximately 50% of operating expenses reported above are recoverable from tenants and are reported gross in both Portfolio Cash Real Estate Revenues and Portfolio Cash Operating Expenses. Pro Forma Portfolio Cash (Adjusted) NOI Margin % has been adjusted to remove recoverable expenses from both revenue and expenses.



As of and for the quarter ended September 30, 2022, square feet in thousands

#### SQUARE FEET BY HEALTH SYSTEM

					Total	Square Feet				
Health System	Property Count	Credit Rating	On-Campus	Adjacent <sup>(1)</sup>	Anchored <sup>(1)</sup>	Unaffiliated Off-Campus	Total	% of Total	% Directly Leased by Health System	Weighted Average Remaining Lease Term
HCA	116	Baa3	9,594	183	318	_	10,095	42.1	24.9	4.1
Memorial Hermann	16	A1	1,709	_	83	_	1,791	7.5	4.1	3.8
Norton Healthcare	10	_	685	328	_	_	1,013	4.2	2.8	4.7
Community Health Systems	16	B3	976	_	_	_	976	4.1	4.7	7.4
Prisma Health System	14	A3	792	_	51	_	843	3.5	2.1	5.9
Thomas Jefferson Univ Hospital	1	A2	694	_	_	_	694	2.9	1.9	4.1
Providence Health & Services	6	A1	610	_	_	_	610	2.5	1.2	1.9
Steward Health	7	_	540	_	_	_	540	2.2	0.9	2.5
Atlantic Health	3	Aa3	_	_	537	_	537	2.2	2.7	10.0
HonorHealth	9	A2	421	107	_	_	528	2.2	0.8	4.1
UPENN Health System	1	Aa3	-	436	_	-	436	1.8	1.0	7.3
Tenet Healthcare	4	B1	295	_	90	_	384	1.6	0.6	4.9
Encompass Health	4	Ba3	310	_	_	_	310	1.3	1.6	1.7
Orlando Health	2	A2	289	_	_	_	289	1.2	0.3	4.8
Ascension Health	5	Aa2	119	_	94	_	213	0.9	0.7	5.3
CommonSpirit	3	Baa1	171	32	_	_	203	0.8	1.0	3.5
Bon Secours Mercy Health	4	A1	60	_	134	_	194	0.8	0.5	4.7
Baylor Scott & White Health	3	Aa3	138	_	49	_	187	0.8	0.4	1.7
Franciscan Alliance	2	Aa3	180	_	_	_	180	0.8	0.8	3.4
Medical Univ of South Carolina	3	Aa3	172	_	_	_	172	0.7	0.9	9.3
Remaining - credit rated	36		1,162	292	680	_	2,134	8.9		
Remaining - not credit rated	31		580	91	409	596	1,676	7.0		
Total	296		19,497	1,469	2,443	596	24,006	100.0	54.0	4.5
% of Total			81.2	6.1	10.2	2.5				
Total Healthcare Affiliated					97.5%					

(1) Denotes whether the medical office building is adjacent (within 0.25 miles) to a hospital campus or anchored (the asset is off-campus, but is 1/3 or more leased to a health system or large physician group).

As of and for the quarter ended September 30, 2022, dollars and square feet in thousands

#### **LEASE EXPIRATION DATA**

		Τα	otal			On-Ca	amp	ous	Off-Campus			
Year	Leased Square Feet			Annualized ase Rent <sup>(1)</sup>	%	Leased Square Feet	Annualized Base Rent <sup>(1)</sup>		Leased Square Feet	Annualize Base Rent <sup>(</sup>		
2022 <sup>(2)</sup>	939	4.3	\$	27,254	5.2	844	\$	24,566	94	\$	2,687	
2023	2,060	9.5		53,792	10.2	1,683		44,409	378		9,383	
2024	2,705	12.5		76,896	14.6	2,233		63,558	472		13,338	
2025	4,686	21.6		93,356	17.7	4,406		85,869	279		7,487	
2026	1,851	8.6		49,639	9.4	1,557		42,171	294		7,469	
2027	1,652	7.6		43,108	8.2	1,305		34,158	347		8,950	
2028	1,899	8.8		37,476	7.1	1,689		32,462	211		5,013	
2029	1,081	5.0		27,079	5.1	834		21,535	246		5,544	
2030	1,127	5.2		29,671	5.6	775		21,162	352		8,508	
2031	1,588	7.3		37,433	7.1	1,205		27,022	382		10,411	
Thereafter	2,056	9.5		51,053	9.7	1,055		28,007	1,001		23,046	
	21,643	100	\$	526,756	100	17,587	\$	424,920	4,057	\$	101,836	

#### **MATERIAL NEAR-TERM PURCHASE OPTIONS**

Maturity Year	Option Date <sup>(3)</sup>	Name	Property Count	MSA	Property Type	Annualized Cas Base Rent <sup>(1)</sup>	sh (Adjusted) NOI	<b>Option Price</b>
2026	10/2025	Innovation	1	San Diego, CA	Medical office	\$ 2,279 \$	1,450 \$	31,700

(1) Annualized Base Rent does not include expense recoveries, additional rent in excess of floors, and non-cash revenue adjustments.

(2) Includes month-to-month and holdover leases.

(3) Reflects the earliest point at which the purchase option can be exercised.

As of September 30, 2022, dollars and square feet in thousands, presented at 100%

#### **3022 LEASING ACTIVITY**

	Leased Ba Square Feet	Annualized ise Rent Per Sq. Ft.	% Change in Cash Rents <sup>(1)</sup>	Tenan Improvement per Sq. Ft. <sup>(</sup>	s Costs per	Average Lease	Trailing Twelve Month Retention Rate
Leased Square Feet as of June 30, 2022	21,611 \$	25.69					
Expirations	(1,229)	26.43					
Renewals, amendments and extensions	1,038	27.12	1.8	\$ 2.1	1 \$ 0.65	81	82.3%
New leases	247	27.40		4.8	3 1.27	74	
Terminations	(24)	25.35					
Leased Square Feet as of September 30, 2022	21,643 \$	25.88					

#### YEAR-TO-DATE LEASING ACTIVITY

	Leased Ba Square Feet	Annualized ase Rent Per Sq. Ft.	% Change in Cash Rents <sup>(1)</sup>	Tenant Improvements per Sq. Ft. <sup>(2)</sup>	Leasing Costs per Sq. Ft. <sup>(2)</sup>	Average Lease Term (Months)	Trailing Twelve Month Retention Rate
Leased Square Feet as of December 31, 2021	21,734 \$	25.43					
Acquisitions	159	22.24					
Dispositions	(283)	33.14					
Planned demolition	(84)	25.55					
Developments placed in service	88	25.32					
Expirations	(2,670)	26.15					
Renewals, amendments and extensions	2,188	26.50	2.1 <sup>(3</sup>	<sup>3)</sup> \$ 2.16	\$ 0.71	67	82.3%
New leases	629	25.70		5.22	1.32	78	
Terminations	(118)	30.66					
Leased Square Feet as of September 30, 2022	21,643 \$	25.88					

(1) For comparative purposes, reflects adjustments for leases that converted to a different lease type upon renewal, amendment or extension of the original lease.

(2) Average cost per lease year.

(3) The year-to-date change in cash rents is negatively affected by renewal of a large tenant under a long term lease that had escalated above market. Excluding this lease, the change in cash rents would have been 2.8% year to date.

As of and for the quarter ended September 30, 2022, square feet in thousands

#### LEASE TYPE

			Leased	Square Feet		
	On-Campus	Adjacent	Anchored	Unaffiliated Off-Campus	Total	% of Total
Triple-Net <sup>(1)</sup>	11,474	663	1,878	117	14,131	65.3
Base Year <sup>(2)</sup>	5,039	493	363	412	6,306	29.1
Gross <sup>(3)</sup>	1,075	11	101	19	1,206	5.6
Total	17,587	1,167	2,342	548	21,643	100.0

#### **OWNERSHIP TYPE**

			Total Squa	re Feet			
	On-Campus	Adjacent	Anchored	Unaffiliated Off-Campus	Total	% of Total	Weighted Average Remaining Lease Term
Ground Lease	8,861	32	442	72	9,406	39.2	79
Fee Simple	10,637	1,437	2,002	525	14,600	60.8	
Total	19,497	1,469	2,443	596	24,006	100.0	

#### **CONTRACTUAL LEASE ESCALATORS**

	Leased Square Feet	% of Square Feet	Escalator %	
Fixed	20,107	92.9	2.8	
CPI	1,537	7.1	6.3	(6)
Total	21,643	100.0	3.1	

#### **PROVIDER SPECIALTY**

Healthpeak	National Benchmark <sup>(4)</sup>
10%	4%
10%	5%
8%	5%
7%	N/A
6%	3%
5%	3%
5%	3%
4%	2%
3%	2%
25%	39%
83%	66%
17%	34%
100%	100%
	10% 10% 8% 7% 6% 5% 5% 4% 3% 25% <b>83%</b>

- (1) Includes both triple-net lease structures, in which the tenant is directly responsible for all operating expenses of the property, and net lease structures, where the tenant is responsible for 100% of their pro rata share of operating expenses.
- (2) A lease structure in which the rental rate includes the tenant's pro rata share of operating expenses. The pro rata share of expenses in the first year of the lease is considered the "base year" and any increase in expenses beyond the "base year" is recoverable from the tenant.
- (3) A lease structure in which the tenant's pro rata share of operating expenses is presumed to be included in the rental rate, with no variability for fluctuations in operating expenses.
- (4) U.S. physicians breakdown from AAMC, 2020 Physician Specialty Data Book.

(5) Includes renewal options.

(6) Includes both pure CPI leases, leases with a CPI floor averaging 2%, and certain leases containing CPI ceilings. The CPI escalator presented above is based on the average year-todate year-over-year change in CPI, which will vary over time and is based on specific lease terms.

### CCRC

As of and for the quarter ended September 30, 2022, dollars in thousands, except REVPOR

#### **INVESTMENTS**

	Property Count	Net Portfolio Investment <sup>(1)</sup>	Portfolio Real Estate Revenues, excluding NREFS	NREF Amortization	Portfolio Cash Opex	Portfolio Adjusted NOI	Units	Occupancy %	REVPOR CCRC	NREF Cash Collections
Operator										
Life Care Services	13	\$ 1,225,693	\$ 85,885	\$ 17,309	\$ (85,489) \$	17,705	6,228	83.2 \$	6,740 \$	20,864
Sunrise Senior Living	2	261,230	16,555	2,397	(14,425)	4,527	1,052	75.1	8,000	3,165
Remaining	_	-	_	_	(350)	(350)	N/A	N/A	N/A	_
Total	15	\$ 1,486,923	\$ 102,440	\$ 19,706	\$ (100,264) \$	21,882	7,280	82.0 \$	6,908 \$	24,029

#### **TOTAL CCRC PORTFOLIO**

					(
	3021	4021	1022	2022	3022
Property count	15	15	15	15	15
Gross Portfolio Investment	\$ 2,219,079 \$	2,243,655 \$	2,253,774 \$	2,267,711 \$	2,270,573
Net Portfolio Investment <sup>(1)</sup>	1,432,162	1,458,768	1,474,262	1,484,906	1,486,923
Units	7,437	7,344	7,344	7,344	7,280
IL, AL, and Memory Care Occupancy %	80.7	80.4	80.8	80.9	82.0
Skilled Nursing Occupancy %	73.5	72.0	81.3	82.3	81.7
Total Occupancy %	79.5	79.0	80.9	81.1	82.0
REVPOR CCRC	\$ 6,714 \$	6,770 \$	7,190 \$	7,032 \$	6,908
REVPOR CCRC excluding NREF Amortization	5,648	5,646	6,126	5,943	5,794
NREF Cash Collections	\$ 24,598 \$	25,585 \$	20,637 \$	28,938 \$	24,029
NREF Amortization	18,900	19,745	18,957	19,444	19,706
Portfolio Real Estate Revenues	\$ 119,037 \$	118,868 \$	128,445 \$	125,569 \$	122,146
Portfolio Operating Expenses before management fee	(95,225)	(92,193)	(94,657)	(98,888)	(96,931)
Management fee	(3,607)	(3,587)	(3,231)	(3,389)	(3,333)
Portfolio NOI <sup>(2)</sup>	\$ 20,206 \$	23,087 \$	30,557 \$	23,292 \$	21,882
Portfolio Cash Real Estate Revenues	\$ 119,037 \$	118,868 \$	128,445 \$	125,569 \$	122,146
Portfolio Cash Operating Expenses before management fee	(94,500)	(90,924)	(94,657)	(98,888)	(96,931)
Management fee	(3,607)	(3,587)	(3,231)	(3,389)	(3,333)
Portfolio Adjusted NOI <sup>(2)</sup>	\$ 20,930 \$	24,356 \$	30,557 \$	6 23,292 \$	21,882
Portfolio Adjusted NOI Margin %	17.6	20.5	23.8	18.5	17.9

(1) Net Portfolio Investment is gross Portfolio Investment as defined in the Glossary less Non-Refundable Entrance Fees ("NREFs") and refundable Entrance Fees, which appear on our Consolidated Balance Sheet in the Deferred revenue line and Accounts payable, accrued liabilities and other liabilities line, respectively. As of September 30, 2022, the balances of NREFs and refundable entrance fees were \$512.0 million and \$271.7 million, respectively.

(2) Includes government grants under the CARES Act for 3021, 4021, 1022, 2022 and 3022 of \$0.0 million, \$0.0 million, \$6.9 million, \$0.2 million, and \$0.0 million, respectively.

# CCRC Same-Store

As of and for the quarter ended September 30, 2022, dollars in thousands, except REVPOR

#### **SAME-STORE**

	3021	4021	1022	2022	3022	Sequential Growth	Year-Over- Year Growth
Property count	15	15	15	15	15	_	_
Net Portfolio Investment	\$ 1,432,162	\$ 1,458,656	\$ 1,474,262	\$ 1,484,906	\$ 1,486,923	0.1%	3.8%
Units	7,437	7,344	7,344	7,344	7,280	(0.9%)	(2.1%)
IL, AL, and Memory Care Occupancy %	80.7	80.4	80.8	80.9	82.0	110 bps	130 bps
Skilled Nursing Occupancy %	73.5	72.0	81.3	82.3	81.7	-60 bps	820 bps
Total Occupancy %	79.5	79.0	80.9	81.1	82.0	90 bps	250 bps
REVPOR CCRC	\$ 6,714	\$ 6,770	\$ 7,190	\$ 7,032	\$ 6,908	(1.8%)	2.9%
REVPOR CCRC excluding NREF Amortization	5,648	5,646	6,126	5,943	5,794	(2.5%)	2.6%
Portfolio Real Estate Revenues	\$ 119,037	\$ 118,868	\$ 128,112	\$ 125,569	\$ 122,146	(2.7%)	2.6%
Portfolio Operating Expenses	(98,405)	(95,719)	(97,398)	(101,834)	(99,914)	(1.9%)	1.5%
Portfolio NOI <sup>(1)</sup>	\$ 20,632	\$ 23,148	\$ 30,714	\$ 23,735	\$ 22,232	(6.3%)	7.8%
Portfolio Cash Real Estate Revenues	\$ 119,037	\$ 118,868	\$ 128,112	\$ 125,569	\$ 122,146	(2.7%)	2.6%
Portfolio Cash Operating Expenses	(97,681)	(94,177)	(97,398)	(101,834)	(99,914)	(1.9%)	2.3%
Portfolio Adjusted NOI <sup>(1)</sup>	\$ 21,356	\$ 24,691	\$ 30,714	\$ 23,735	\$ 22,232	(6.3%)	4.1%
Portfolio Adjusted NOI Margin %	17.9	20.8	24.0	18.9	18.2	-70 bps	30 bps

#### PRO FORMA SAME-STORE (EXCLUDING CARES ACT RECEIPTS)

	3021	4021	1022	2022	3022	Sequential Growth	Year-Over- Year Growth
REVPOR CCRC	\$ 6,713	\$ 6,770	\$ 6,822	\$ 7,020	\$ 6,908	(1.6%)	2.9%
REVPOR CCRC excluding NREF Amortization <sup>(2)</sup>	5,647	5,646	5,758	5,931	5,794	(2.3%)	2.6%
Portfolio Real Estate Revenues	\$ 119,022	\$ 118,868	\$ 121,560	\$ 125,360	\$ 122,143	(2.6%)	2.6%
Portfolio Operating Expenses	(98,405)	(95,719)	(97,398)	(101,834)	(99,914)	(1.9%)	1.5%
Portfolio NOI	\$ 20,617	\$ 23,148	\$ 24,162	\$ 23,526	\$ 22,228	(5.5%)	7.8%
Portfolio Cash Real Estate Revenues	\$ 119,022	\$ 118,868	\$ 121,560	\$ 125,360	\$ 122,143	(2.6%)	2.6%
Portfolio Cash Operating Expenses	(97,681)	(94,177)	(97,398)	(101,834)	(99,914)	(1.9%)	2.3%
Portfolio Adjusted NOI	\$ 21,341	\$ 24,691	\$ 24,162	\$ 23,526	\$ 22,228	(5.5%)	4.2%
Portfolio Adjusted NOI Margin %	17.9	20.8	19.9	18.8	18.2	-60 bps	30 bps
· · · · · · · · · · · · · · · · · · ·		2010		1010		20 200	00 500

(1) Includes government grants under the CARES Act for 3021, 4021, 1022, 2022 and 3022 of \$0.0 million, \$0.0 million, \$6.6 million, \$0.2 million, and \$0.0 million, respectively.

(2) REVPOR CCRC was impacted by taking skilled nursing, assisted living and memory care units out of service. Pro Forma REVPOR CCRC excluding NREF amortization growth for our non-SNF care types (IL, AL, and memory care) is 4.2% year-over-year.

# Other

As of and for the quarter ended September 30, 2022, dollars in thousands, except REVPOR

#### SOVEREIGN WEALTH FUND SENIOR HOUSING JV AT SHARE

		3021	4021	1022	2022	3022
Property count		19	19	19	19	19
Investment	\$	455,743 \$	457,870 \$	458,352 \$	460,543 \$	462,219
Units		3,354	3,354	3,354	3,354	3,354
Occupancy %		74.3	74.8	75.8	75.8	77.5
REVPOR Other	\$	4,000 \$	4,118 \$	4,278 \$	4,234 \$	4,276
Portfolio Real Estate Revenues	\$	17,109 \$	17,971 \$	18,360 \$	18,215 \$	18,839
Portfolio Operating Expenses before management fee		(12,617)	(12,547)	(13,193)	(13,282)	(13,708)
Management fee		(821)	(823)	(862)	(868)	(891)
Portfolio NOI <sup>(1)</sup>	\$	3,672 \$	4,602 \$	4,305 \$	4,065 \$	4,240
Portfolio Cash Real Estate Revenues	\$	17,121 \$	17,967 \$	18,383 \$	18,301 \$	18,905
Portfolio Cash Operating Expenses before management fe	е	(12,729)	(12,574)	(13,224)	(13,313)	(13,698)
Management fee		(821)	(823)	(862)	(868)	(891)
Portfolio Cash (Adjusted) NOI <sup>(1)</sup>	\$	3,571 \$	4,570 \$	4,296 \$	4,119 \$	4,316
Portfolio Cash (Adjusted) NOI Margin %		20.9	25.4	23.4	22.5	22.8

#### **PRO FORMA (EXCLUDING CARES ACT RECEIPTS)**

<b>1022</b> 4,210 \$	<b>2022</b> 4,234 \$	<b>3022</b> 4,232
4,210 \$	4,234 \$	4,232
18,045 \$	s 18,215 <b>\$</b>	18,657
(13,193)	(13,282)	(13,708)
(862)	(868)	(891)
3,990 \$	6	4,058
18,067 \$	5 18,301 \$	18,722
(13,224)	(13,313)	(13,698)
(862)	(868)	(891)
3,981 \$	6 4,119 \$	4,134
22.0	22.5	22.1
	(13,193) (862) 3,990 \$ 18,067 \$ (13,224) (862) 3,981 \$	(13,193) (13,282) (862) (868) 3,990 \$ 4,065 \$ 18,067 \$ 18,301 \$ (13,224) (13,313) (862) (868) 3,981 \$ 4,119 \$

#### **DEBT INVESTMENTS**

				Weigh	ted Average
	Investment <sup>(2)</sup>	Inte	erest Income	Yield	Maturity in Years <sup>(3)</sup>
Seller financing loans	\$ 358,526	\$	5,541	5.3%	0.5
Other	22,666		422	7.5%	0.3
Total Debt Investments	\$ 381,192	\$	5,964	5.4%	0.5

- Includes government grants under the CARES Act for 3021, 4021, 1022, 2022 and 3022 of \$0.0 million, \$0.7 million, \$0.3 million, \$0.0 million, and \$0.2 million, respectively.
- (2) Excludes \$5.1 million of estimated reserves for loan losses under the current expected credit losses accounting standard in accordance with ASC 326, and resident loans on CCRC entrance fee contracts of \$29.4 million.
- (3) Weighted average maturity in years is based on initial maturity and excludes extension options. Including extension options weighted average maturity would be 1.0 years.

# 2022 Guidance & Additional Items<sup>(1)</sup>

Projected full year 2022, dollars in millions, except per share

Bolded items represent updates from previous Guidance ranges and assumptions

	Full Year 2022 Guidance (November 1, 2022)
2022 Guidance	
Diluted earnings per common share	\$0.94 - \$0.96
Diluted Nareit FFO per common share	\$1.67 - \$1.69
Diluted FFO as adjusted per common share	\$1.72 - \$1.74
Total Portfolio year-over-year Same-Store Cash NOI	4.50% – 5.50%

Total Portfolio Year-Over-Year Same-Store Cash NOI Components				
	% of NOI			
Life Science	48%	4.75% – 5.25%		
Medical Office	40%	3.75% – 4.25%		
CCRC <sup>(2)(3)</sup>	12%	6.00% – 10.00%		
Total Portfolio <sup>(3)</sup>	100%	4.50% - 5.50%		

	Additional 2022 Guidance Assumptions
Other Supplemental Information - AFFO Addition (Reduction)	
Amortization of stock-based compensation	\$17 – \$19
Amortization of deferred financing costs	\$9 – \$13
Straight-line rents	(\$48) – (\$54)
AFFO capital expenditures	(\$95) – (\$110)
Deferred income taxes	\$0 - (\$4)
Other AFFO adjustments	(\$25) – (\$35)

Capital Expenditures (excluding AFFO Capital Expenditures) <sup>(4)</sup>						
1st generation TIs / revenue enhancing / ICE / casualty \$150 - \$200						
Development <sup>(5)</sup>	\$425 – \$525					
Redevelopment <sup>(5)</sup>	\$125 - \$175					
CCRC Non-Refundable Entrance Fees						
Non-refundable entrance fee amortization	\$77 – \$83					
Non-refundable entrance fee cash receipts	<b>\$95 - \$105</b>					

Other Items	
Interest income	\$20 - \$25
General and administrative	\$90 - \$95
Interest expense	\$160 – \$175
Unconsolidated SWF SH JV Cash NOI <sup>(6)</sup>	\$15 – \$20

Average	LIBOR	Assum	ptions

4Q 2022

4.0%

- (1) Range of outcomes presented below incorporate various items shown on this page. Other items that may impact the range of outcomes include, but are not limited to: timing of acquisitions / dispositions / loan repayments and potential changes to interest rates.
- (2) CCRC Year-Over-Year Same-Store Cash NOI guidance updated in part due to impact from Hurricane Ian.
- (3) Includes \$6.8 million of CARES Act grants received year-to-date in 2022 related to CCRCs. 2021 included \$1.4 million of CARES Act grants related to the CCRC Same-Store pool. Excluding CARES Act grants, our 2022 Same-Store Cash NOI guidance for CCRC and Total Portfolio would be 1.00% – 5.00% and 4.00% – 5.00%, respectively.
- (4) Includes our share of Unconsolidated JVs.
- (5) Excludes ~\$40 million of capitalized interest related to our share of development and redevelopment spend.
- (6) Excluded from the 2022 Same-Store pool.

### Glossary

#### Adjusted Fixed Charge Coverage\*

Adjusted EBITDAre divided by Fixed Charges. Adjusted Fixed Charge Coverage is a supplemental measure of liquidity and our ability to meet interest payments on our outstanding debt and pay dividends to our preferred stockholders, if applicable. Our various debt agreements contain covenants that require us to maintain ratios similar to Adjusted Fixed Charge Coverage and credit rating agencies utilize similar ratios in evaluating and determining the credit rating on certain of our debt instruments. Adjusted Fixed Charge Coverage is subject to the same limitations and qualifications as Adjusted EBITDAre and Fixed Charges.

#### Adjusted Funds From Operations ("AFFO")\*

See the "Adjusted Funds From Operations" definition included in the accompanying Discussion and Reconciliations of Non-GAAP Financial Measures for information regarding AFFO.

#### Annualized Base Rent

The most recent month's (or subsequent month's if acquired in the most recent month) base rent including additional rent floors, cash income from DFLs, and/or interest income annualized for 12 months. Annualized Base Rent includes the Company's share of unconsolidated JVs calculated on the same basis and excludes properties in our CCRC segment, properties sold or held for sale during the quarter, and noncontrolling interests' share of consolidated JVs calculated on the same basis. Further, Annualized Base Rent does not include expense recoveries, additional rents in excess of floors, and non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, DFL non-cash interest and deferred revenues). We use Annualized Base Rent for the purpose of determining Lease Expirations and Debt Investment Maturities.

#### **Completion Date - Development/Redevelopment**

For Developments, management's estimate of the period the core and shell structure improvements are expected to be or have been completed. For Redevelopments, management's estimate of the period in which major construction activity in relation to the scope of the project has been or will be substantially completed and excludes the completion of tenant improvements.

#### **Consolidated Debt**

The carrying amount of bank line of credit, commercial paper, term loans, senior unsecured notes, and mortgage debt, as reported in our consolidated financial statements.

#### Consolidated Gross Assets\*

The carrying amount of total assets, excluding investments in and advances to our unconsolidated JVs, after adding back accumulated depreciation and amortization, as reported in our consolidated financial statements. Consolidated Gross Assets is a supplemental measure of our financial position, which, when used in conjunction with debt-related measures, enables both management and investors to analyze our leverage and to compare our leverage to that of other companies.

#### **Consolidated Secured Debt**

Mortgage and other debt secured by real estate, as reported in our consolidated financial statements.

#### Continuing Care Retirement Community ("CCRC")

A senior housing facility which provides at least three levels of care (i.e., independent living, assisted living and skilled nursing).

#### **Debt Investments**

Loans secured by a direct interest in real estate and mezzanine loans.

#### Development

Includes ground-up construction. Newly completed developments, are considered Stabilized at the earlier of lease-up (typically when the tenant(s) controls the physical use of 80% of the space) or 24 months from the date the property is placed in service.

#### Direct Financing Lease ("DFL")

Lease for which future minimum lease payments are recorded as a receivable and the difference between the future minimum lease payments and the estimated residual values less the cost of the properties is recorded as unearned income. Unearned income is deferred and amortized to income over the lease terms to provide a constant yield.

#### EBITDAre and Adjusted EBITDAre\*

EBITDAre, or EBITDA for Real Estate, is a supplemental performance measure defined by the National Association of Real Estate Investment Trusts ("Nareit") and intended for real estate companies. It represents earnings before interest expense, income taxes, depreciation and amortization, gains or losses from sales of depreciable property (including gains or losses on change in control), and impairment charges (recoveries) related to depreciable property. Adjusted EBITDAre is defined as EBITDAre excluding other impairments (recoveries) and other losses (gains), transaction-related items, prepayment costs (benefits) associated with early retirement or payment of debt, restructuring and severance related charges, litigation costs (recoveries), casualty-related charges (recoveries), stock compensation expense, and foreign currency remeasurement losses (gains), adjusted to reflect the impact of transactions that closed during the quarter as if the transactions were completed at the beginning of the quarter. EBITDAre and Adjusted EBITDAre include our pro rata share of our unconsolidated JVs presented on the same basis.

#### Enterprise Debt\*

Consolidated Debt plus our pro rata share of total debt from our unconsolidated JVs. Enterprise Debt is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies. Our pro rata share of total debt from our unconsolidated JVs is not intended to reflect our actual liability or ability to access assets should there be a default under any or all such loans or a liquidation of the JVs.

#### Enterprise Gross Assets\*

Consolidated Gross Assets plus our pro rata share of total gross assets from our unconsolidated JVs, after adding back accumulated depreciation and amortization. Enterprise Gross Assets is a supplemental measure of our financial position, which, when used in conjunction with debt-related measures, enables both management and investors to analyze our leverage and to compare our leverage to that of other companies.

#### **Enterprise Secured Debt\***

Consolidated Secured Debt plus our pro rata share of mortgage debt from our unconsolidated JVs. Enterprise Secured Debt is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies. Our pro rata share of Enterprise Secured Debt from our unconsolidated JVs is not intended to reflect our actual liability or ability to access assets should there be a default under any or all such loans or a liquidation of the JVs.

#### **Entrance Fees**

Certain of our CCRC communities have residency agreements which require the resident to pay an upfront entrance fee prior to taking occupancy at the community. For net income, NOI, Adjusted NOI, Nareit FFO, FFO as Adjusted, and AFFO, the non-refundable portion of the entrance fee is recorded as deferred entrance fee revenue and amortized over the estimated stay of the resident based on an actuarial valuation. The refundable portion of a resident's entrance fee is generally refundable within a certain number of months or days following contract termination or upon the sale of the unit. All refundable amounts due to residents at any time in the future are classified as liabilities.

### Glossary

#### Financial Leverage\*

Enterprise Debt divided by Enterprise Gross Assets. Financial Leverage is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies.

#### Fixed Charges\*

Total interest expense plus capitalized interest plus preferred stock dividends (if applicable). Fixed Charges also includes our pro rata share of the interest expense plus capitalized interest plus preferred stock dividends (if applicable) of our unconsolidated JVs. Fixed Charges is a supplemental measure of our interest payments on outstanding debt and dividends to preferred stockholders for purposes of presenting Fixed Charge Coverage and Adjusted Fixed Charge Coverage. Fixed Charges is subject to limitations and qualifications, as, among other things, it does not include all contractual obligations.

#### Funds From Operations ("Nareit FFO") and FFO as Adjusted\*

See the "Funds From Operations" definition included in the accompanying Discussion and Reconciliations of Non-GAAP Financial Measures for information regarding Nareit FFO and FFO as Adjusted.

#### Healthcare Affiliated

Represents properties that are on-campus or adjacent to a healthcare system and properties that are leased 1/3 or more to a health system or physician group.

#### Initial Capital Expenditures ("ICE")

Expenditures required to bring a newly acquired property up to standard. The expenditures are typically identified during underwriting and incurred within the first year of ownership.

#### Investment and Portfolio Investment\*

Represents: (i) the carrying amount of real estate assets and intangibles, after adding back accumulated depreciation and amortization and (ii) the carrying amount of DFLs and Debt Investments. Portfolio Investment also includes our pro rata share of the real estate assets and intangibles held in our unconsolidated JVs, presented on the same basis as Investment, and excludes noncontrolling interests' pro rata share of the real estate assets and intangibles held in our consolidated JVs, presented on the same basis. Investment and Portfolio Investment exclude land held for development.

#### Metropolitan Statistical Areas ("MSA")

Metropolitan Statistical Areas are geographic entities delineated by the Office of Management and Budget for use by Federal Statistical agencies in collecting, tabulating, and publishing Federal statistics. A metro area contains a core urban area of 50,000 or more population, consists of one or more counties and includes the counties containing the core urban area, as well as any adjacent counties that have a high degree of social and economic integration (as measured by commuting to work) with the urban core.

#### Net Debt\*

Enterprise Debt less the carrying amount of cash and cash equivalents, restricted cash, and expected net proceeds from the future settlement of shares issued through our equity forward contracts, as reported in our consolidated financial statements and our pro rata share of cash and cash equivalents and restricted cash from our unconsolidated JVs. Net Debt is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies.

#### Net Debt to Adjusted EBITDAre\*

Net Debt divided by Adjusted EBITDAre is a supplemental measure of our ability to decrease our debt. Because we may not be able to use our cash to reduce our debt on a dollar-for-dollar basis, this measure may have material limitations.

#### Net Operating Income ("NOI") and Cash (Adjusted) NOI\*

NOI is defined as real estate revenues (inclusive of rental and related revenues, resident fees and services, income from direct financing leases, and government grant income and exclusive of interest income), less property level operating expenses; NOI excludes all other financial statement amounts included in net income (loss). Cash (Adjusted) NOI is calculated as NOI after eliminating the effects of straight-line rents, DFL non-cash interest, amortization of market lease intangibles, termination fees, actuarial reserves for insurance claims that have been incurred but not reported, and the impact of deferred community fee income and expense. NOI and Cash (Adjusted) NOI include the Company's pro rata share of NOI and Cash (Adjusted) NOI from its unconsolidated JVs and exclude noncontrolling interests' pro rata share of NOI and Cash (Adjusted) NOI from consolidated joint ventures. See the "Net Operating Income ("NOI") and Cash (Adjusted) NOI" definition included in the accompanying Discussion and Reconciliation of Non-GAAP Financial Measures for further information regarding the impact of the Company's pro rata share on these measures.

#### Occupancy

For life science facilities and medical office buildings, Occupancy represents the percentage of total rentable square feet leased where leases have commenced, including month-to-month leases, as of the end of the period reported. For senior housing facilities, Occupancy represents the facilities' average operating Occupancy for the most recent calendar quarter (year-to-date for year-to-date SS) available based on units. The percentages shown are weighted to reflect our share and exclude newly completed facilities under lease-up, facilities acquired or transitioned to new operators during the relevant period, vacant facilities, facilities held for sale, facilities for which agreement has been reached to change reporting structure, and facilities for which data is not available or meaningful. All facility financial performance data was derived solely from information provided by operators/tenants/borrowers without independent verification by us.

#### Portfolio Adjusted NOI\*

Portfolio Adjusted NOI is Portfolio Cash Real Estate Revenues less Portfolio Cash Operating Expenses.

#### Portfolio Operating Expenses and Portfolio Cash Operating Expenses\*

Portfolio Operating Expenses and Portfolio Cash Operating Expenses are non-GAAP supplemental measures. Portfolio Operating Expenses represent property level operating expenses (which exclude transition costs). Portfolio Operating Expenses include consolidated operating expenses plus the Company's pro rata share of operating expenses from its unconsolidated JVs less noncontrolling interests' pro rata share of operating expenses from consolidated JVs. Portfolio Cash Operating Expenses represent Portfolio Operating Expenses after eliminating the effects of straight-line rents, lease termination fees, actuarial reserves for insurance claims that have been incurred but not reported, and the impact of deferred community fee expense.

#### Portfolio Income\*

Cash (Adjusted) NOI plus interest income plus our pro rata share of Cash (Adjusted) NOI from our unconsolidated JVs less noncontrolling interests' pro rata share of Cash (Adjusted) NOI from consolidated JVs. Management believes that Portfolio Income is an important supplemental measure because it provides relevant and useful information regarding our performance; specifically, it is a measure of our property level profitability of the Company inclusive of interest income. Management believes that net income (loss) is the most directly comparable GAAP measure to Portfolio Income. Portfolio Income should not be viewed as an alternative measure of operating performance to net income (loss) as defined by GAAP since it does not reflect various excluded items.

### Glossary

### Portfolio Real Estate Revenues\* and Portfolio Cash Real Estate Revenues\*

Portfolio Real Estate Revenues and Portfolio Cash Real Estate Revenues are non-GAAP supplemental measures. Portfolio Real Estate Revenues include rental related revenues, resident fees and services, income from DFLs, and government grant income which is included in Other income (expense), net in our Consolidated Statement of Operations. Portfolio Real Estate Revenues include the Company's pro rata share from unconsolidated JVs presented on the same basis and exclude noncontrolling interests' pro rata share from consolidated JVs presented on the same basis. Portfolio Cash Real Estate Revenues include Portfolio Real Estate Revenues after eliminating the effects of straight-line rents, DFL non-cash interest, amortization of market lease intangibles, lease termination fees, and the impact of deferred community fee income.

#### Redevelopment

Properties that incur major capital expenditures to significantly improve, change the use, or reposition the property pursuant to a formal redevelopment plan. Newly completed redevelopments, are considered Stabilized at the earlier of lease-up (typically when the tenant(s) controls the physical use of 80% of the space) or 24 months from the date the property is placed in service.

#### **Retention Rate**

The ratio of total renewed square feet to the total square feet expiring and available for lease, excluding the square feet for tenant leases terminated for default or buy-out prior to the expiration of the lease and leases in assets designated as Held for Sale.

#### **REVPOR CCRC\***

The 3-month average Cash Real Estate Revenues per occupied unit excluding Cash NREFs for the most recent period available. REVPOR CCRC excludes newly completed assets under leaseup, assets sold, acquired or converted to a new operating structure during the relevant period, assets in redevelopment, assets that are held for sale, and assets that experienced a casualty event that significantly impacted operations. REVPOR cannot be derived from the information presented for the CCRC portfolio as units reflect 100% of the unit capacities for unconsolidated JVs and revenue is at the Company's pro rata share. All facility occupancy data was derived solely from information provided by operators without independent verification by us.

#### **REVPOR Other\***

The 3-month average Cash Real Estate Revenues per occupied unit for the most recent period available. REVPOR Other excludes newly completed assets under lease-up, assets sold, acquired or converted to a new operating structure during the relevant period, assets in redevelopment, assets that are held for sale, and assets that experienced a casualty event that significantly impacted operations. REVPOR cannot be derived from the information presented for the Other portfolio as units reflect 100% of the unit capacities for unconsolidated JVs and revenue is at the Company's pro rata share. All facility occupancy data was derived solely from information provided by operators without independent verification by us.

#### **RIDEA**

A structure whereby a taxable REIT subsidiary is permitted to rent a healthcare facility from its parent REIT and hire an independent contractor to operate the facility.

\* Non-GAAP Supplemental Measures

Reconciliations, definitions, and important discussions regarding the usefulness and limitations of the Non-GAAP Financial Measures used in this report can be found at <a href="https://ir.healthpeak.com/quarterly-results">https://ir.healthpeak.com/quarterly-results</a>.

#### Same-Store ("SS")\*

Same-Store NOI and Cash (Adjusted) NOI information allows us to evaluate the performance of our property portfolio under a consistent population by eliminating changes in the composition of our consolidated portfolio of properties. Same-Store Adjusted NOI excludes amortization of deferred revenue from tenant-funded improvements and certain non-property specific operating expenses that are allocated to each operating segment on a consolidated basis. Properties are included in Same-Store once they are stabilized for the full period in both comparison periods. Newly acquired operating assets are generally considered stabilized at the earlier of lease-up (typically when the tenant(s) control(s) the physical use of at least 80% of the space and rental payments have commenced) or 12 months from the acquisition date. Newly completed developments and redevelopments are considered stabilized at the earlier of lease-up or 24 months from the date the property is placed in service. Properties that experience a change in reporting structure are considered stabilized after 12 months in operations under a consistent reporting structure. A property is removed from Same-Store when it is classified as held for sale, sold, placed into redevelopment, experiences a casualty event that significantly impacts operations, a change in reporting structure or operator transition has been agreed to, or a significant tenant relocates from a Same-Store property to a non Same-Store property and that change results in a corresponding increase in revenue. We do not report Same-Store metrics for our other non-reportable segments.

#### Secured Debt Ratio\*

Enterprise Secured Debt divided by Enterprise Gross Assets. Secured Debt Ratio is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies.

#### Share of Consolidated Joint Ventures ("JVs")

Noncontrolling interests' pro rata share information is prepared by applying noncontrolling interests' actual ownership percentage for the period and is intended to reflect noncontrolling interests' proportionate economic interest in the financial position and operating results of properties in our portfolio.

#### Share of Unconsolidated Joint Ventures

Our pro rata share information is prepared by applying our actual ownership percentage for the period and is intended to reflect our proportionate economic interest in the financial position and operating results of properties in our portfolio.

#### Stabilized / Stabilization

Newly acquired operating assets are generally considered Stabilized at the earlier of lease-up (typically when the tenant(s) control(s) the physical use of at least 80% of the space and rental payments have commenced) or 12 months from the acquisition date. Newly completed developments and redevelopments are considered Stabilized at the earlier of lease-up or 24 months from the date the property is placed in service. Properties that experience a change in reporting structure are considered Stabilized after 12 months in operations under a consistent reporting structure.

#### **Total Market Equity**

The total number of outstanding shares of our common stock multiplied by the closing price per share of our common stock on the New York Stock Exchange as of period end, plus the total number of convertible partnership units multiplied by the closing price per share of our common stock on the New York Stock Exchange as of period end (adjusted for stock splits).

#### Units/Square Feet/Capacity

Senior housing facilities are measured in available units (e.g., studio, one or two bedroom units). Life science facilities and medical office buildings are measured in square feet, excluding square footage for development or square footage removed from service for redevelopment properties prior to completion. Capacities are presented at 100% ownership share.

## **Debt Ratios**

### Adjusted EBITDAre and Adjusted Fixed Charge Coverage

Dollars in thousands

#### NET INCOME TO ADJUSTED EBITDAre

	 Months Ended nber 30, 2022
Net income (loss)	\$ 357,986
Interest expense	44,078
Income tax expense (benefit) <sup>(1)</sup>	(3,724)
Depreciation and amortization	173,190
Other depreciation and amortization	1,315
Loss (gain) on sales of real estate <sup>(1)</sup>	5,280
Loss (gain) upon change of control	(311,438)
Share of unconsolidated JV:	
Interest expense	(272)
Income tax expense (benefit)	118
Depreciation and amortization	8,704
Loss (gain) on sale of real estate from unconsolidated JVs	239
EBITDAre	\$ 275,476
Transaction-related items, net	728
Other impairments (recoveries) and losses (gains) <sup>(2)</sup>	3,407
Casualty-related charges (recoveries)	5,380
Stock-based compensation amortization expense	4,614
Impact of transactions closed during the quarter <sup>(3)</sup>	(8)
Adjusted EBITDAre	\$ 289,597
ADJUSTED FIXED CHARGE COVERAGE	
Interest expense, including unconsolidated JV interest expense at share	43,806
Capitalized interest	10,911
Fixed Charges	\$ 54,717
Adjusted Fixed Charge Coverage	5.3x

- (1) This amount can be reconciled by combining the balances from the corresponding line of the <u>Consolidated Statements</u> <u>of Operations</u> of this Earnings Release and Supplemental Report and the detailed financial information in the Discontinued Operations Reconciliation section included in the corresponding Discussion and Reconciliation of Non-GAAP Financial Measures at <u>http://ir.healthpeak.com/</u>.
- (2) Adjustment includes reserves for loan losses recognized in impairments and loan loss reserves (recoveries), net in the Consolidated Statements of Operations.
- (3) Adjustment reflects the impact of transactions that closed during the quarter as if the transactions were completed at the beginning of the quarter.

## **Debt Ratios**

As of and for the quarter ended September 30, 2022, dollars in thousands

#### ENTERPRISE DEBT AND NET DEBT

	Septer	nber 30, 2022
Bank line of credit and commercial paper	\$	1,585,333
Senior unsecured notes		4,657,651
Mortgage debt		347,987
Consolidated Debt	\$	6,590,971
Share of unconsolidated JV mortgage debt		39,776
Enterprise Debt	\$	6,630,747
Cash and cash equivalents <sup>(1)</sup>		(114,624)
Share of unconsolidated JV cash and cash equivalents		(24,463)
Restricted cash		(54,500)
Share of unconsolidated JV restricted cash		(3,057)
Expected net proceeds from forward contracts		(308,491)
Net Debt	\$	6,125,612
FINANCIAL LEVERAGE		

	Se	September 30, 2022	
Enterprise Debt	\$	6,630,747	
Enterprise Gross Assets		19,391,385	
Financial Leverage		34.2%	

**SECURED DEBT RATIO** 

	Septem	September 30, 2022	
Mortgage debt	\$	347,987	
Share of unconsolidated JV mortgage debt		39,776	
Enterprise Secured Debt	\$	387,763	
Enterprise Gross Assets		19,391,385	
Secured Debt Ratio		2.0%	

#### **NET DEBT TO ADJUSTED EBITDAre**

	Se	September 30, 2022	
Net Debt	\$	6,125,612	
Annualized Adjusted EBITDAre <sup>(2)</sup>		1,158,388	
Net Debt to Adjusted EBITDAre		5.3x	

- (1) Includes cash and cash equivalents of \$2 million on assets classified as discontinued operations.
- (2) Represents the current quarter Adjusted EBITDAre multiplied by a factor of four.

# Information

### **BOARD OF DIRECTORS**

#### **BRIAN G. CARTWRIGHT**

Chairman of the Board, Healthpeak Properties, Inc. Former General Counsel, U.S. Securities and Exchange Commission

#### **KATHERINE M. SANDSTROM**

Vice Chair of the Board, Healthpeak Properties, Inc. Former Senior Managing Director, Heitman LLC

**SCOTT M. BRINKER** President and Chief Executive Officer, Healthpeak Properties, Inc.

#### **CHRISTINE N. GARVEY**

Former Global Head of Corporate Real Estate Services, Deutsche Bank AG

### EXECUTIVE MANAGEMENT

SCOTT M. BRINKER President Chief Executive Officer

PETER A. SCOTT Chief Financial Officer

THOMAS M. KLARITCH Chief Operating Officer

JEFFREY H. MILLER General Counsel

#### **R. KENT GRIFFIN, JR.**

Managing Director, PHICAS Investors Former President, BioMed Realty Trust, Inc.

#### **DAVID B. HENRY**

Former Vice Chairman and Chief Executive Officer, Kimco Realty Corporation

#### SARA GROOTWASSINK LEWIS

Founder and Chief Executive Officer, Lewis Corporate Advisors, LLC

SCOTT R. BOHN Chief Development Officer Co-Head of Life Science

ADAM G. MABRY Chief Investment Officer

SHAWN G. JOHNSTON Executive Vice President Chief Accounting Officer

LISA A. ALONSO Executive Vice President Chief Human Resources Officer



### Forward-Looking Statements & Risk Factors

Statements contained in this supplemental report that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements regarding our and our officers' intent, belief or expectation as identified by the use of words such as "may," "will," "project," "expect," "believe," "intend," "anticipate," "seek," "target," "forecast," "plan," "potential," "estimate," "could," "would," "should" and other comparable and derivative terms or the negatives thereof. Examples of forward-looking statements include, among other things: (i) statements regarding timing, outcomes and other details relating to current, pending or contemplated acquisitions, dispositions, transitions, developments, redevelopments, densifications, joint venture transactions, leasing activity and commitments, capital recycling plans, financing activities, or other transactions; and (ii) the information presented in the section titled "2022 Guidance and Additional Items." Pending acquisitions, dispositions, joint venture transactions, leasing activity, and financing activity, including those subject to binding agreements, remain subject to closing conditions and may not be completed within the anticipated timeframes or at all. Forwardlooking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could significantly affect our future financial condition and results of operations. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. Further, we cannot guarantee the accuracy of any such forward-looking statement contained in this supplemental report, and such forward-looking statements are subject to known and unknown risks and uncertainties that are difficult to predict. These risks and uncertainties include, but are not limited to: epidemics, pandemics or other infectious diseases, including Covid, and health and safety measures intended to reduce their spread, and how guickly and to what extent normal economic and operating conditions can resume within the markets in which we operate; the ability of our existing and future tenants, operators and borrowers to conduct their respective businesses in a manner sufficient to maintain or increase their revenues and manage their expenses in order to generate sufficient income to make rent and loan payments to us and our ability to recover investments made, if applicable, in their operations; increased competition, operating costs and market changes affecting our tenants, operators and borrowers; the financial condition of our tenants, operators and borrowers, including potential bankruptcies and downturns in their businesses, and their legal and regulatory proceedings; our concentration of real estate investments in the healthcare property sector, which makes us more vulnerable to a downturn in a specific sector than if we invested in multiple industries and exposes us to the risks inherent in illiquid investments; our ability to identify and secure replacement tenants and operators and the potential renovation costs and regulatory approvals associated therewith; our property development, redevelopment and tenant improvement activity risks, including project abandonments, project delays and lower profits than expected; changes within the life science industry; high levels of regulation, funding requirements, expense and uncertainty faced by our life science tenants; the ability of the hospitals on whose campuses our MOBs are located and their affiliated healthcare systems to remain competitive or financially viable; our ability to maintain or expand our hospital and health system client relationships; operational risks associated with third party management contracts, including the additional regulation and liabilities of our RIDEA lease structures; economic and other conditions that negatively affect geographic areas from which we recognize a greater percentage of our revenue; uninsured or underinsured losses, which could result in significant losses and/or performance declines by us or our tenants and operators; our investments in joint ventures and unconsolidated entities, including our lack of sole decision making authority and our reliance on our partners' financial condition and continued cooperation; our use of fixed rent escalators, contingent rent provisions and/or rent escalators based on the Consumer Price Index; competition for suitable healthcare properties to grow our investment portfolio; our ability to foreclose on collateral securing our real estate-related loans; our ability to make material acquisitions and successfully integrate them; the potential impact on us and our tenants, operators and borrowers from litigation matters, including rising liability and insurance costs; an increase in our borrowing costs, including due to higher interest rates; the availability of external capital on acceptable terms or at all, including due to rising interest rates, changes in our credit ratings and the value of our common stock, volatility or uncertainty in the capital markets, and other factors; cash available for distribution to stockholders and our ability to make dividend distributions at expected levels; our ability to manage our indebtedness level and covenants in and changes to the terms of such indebtedness; changes in global, national and local economic and other conditions; laws or regulations prohibiting eviction of our tenants; Continued



South S

FOUNDRY & LUX

### Forward-Looking Statements & Risk Factors (concluded)


the failure of our tenants, operators and borrowers to comply with federal, state and local laws and regulations, including resident health and safety requirements, as well as licensure, certification and inspection requirements; required regulatory approvals to transfer our senior housing properties; compliance with the Americans with Disabilities Act and fire, safety and other regulations; the requirements of, or changes to, governmental reimbursement programs such as Medicare or Medicaid; legislation to address federal government operations and administration decisions affecting the Centers for Medicare and Medicaid Services; our participation in the CARES Act Provider Relief Fund and other Covid-related stimulus and relief programs; provisions of Maryland law and our charter that could prevent a transaction that may otherwise be in the interest of our stockholders; environmental compliance costs and liabilities associated with our real estate investments; our ability to maintain our gualification as a real estate investment trust ("REIT"); changes to U.S. federal income tax laws, and potential deferred and contingent tax liabilities from corporate acquisitions; calculating non-REIT tax earnings and profits distributions; ownership limits in our charter that restrict ownership in our stock; the loss or limited availability of our key personnel; our reliance on information technology systems and the potential impact of system failures, disruptions or breaches; and other risks and uncertainties described from time to time in our Securities and Exchange Commission (SEC) filings. Except as required by law, we do not undertake, and hereby disclaim, any obligation to update any forwardlooking statements, which speak only as of the date on which they are made.

The information in this supplemental report should be read in conjunction with our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other information filed with the SEC. The Reporting Definitions (and Reconciliations of Non-GAAP Financial Measures) are an integral part of the information presented herein. You can access these documents on our website, www.healthpeak.com, free of charge, as well as amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The information contained on our website is not incorporated by reference into, and should not be considered a part of, this supplemental report.

In addition, the SEC maintains a website that contains reports, proxy and information statements, and other information regarding issuers, including the Company, that file electronically with the SEC at www.sec.gov.

This supplemental report also includes market and industry data that the Company has obtained from market research, publicly available information and industry publications. The accuracy and completeness of such information are not guaranteed. The market and industry data is often based on industry surveys and preparers' experience in the industry. Similarly, although the Company believes that the surveys and market research that others have performed are reliable, such surveys and market research are subject to assumptions, estimates and other uncertainties and the Company has not independently verified this information.

For more information, contact Andrew Johns, Senior Vice President - Investor Relations, at (720) 428-5050.



#### Corporate HQ, Denver, CO

5050 South Syracuse Street, Suite 800 Denver, CO 80237 (720) 428 - 5050

#### Irvine, CA

1920 Main Street, Suite 1200 Irvine, CA 92614

#### Nashville, TN

3000 Meridian Boulevard, Suite 200 Franklin, TN 37067

#### South San Francisco, CA

2000 Sierra Point Parkway, Suite 100 Brisbane, CA 94005

San Diego, CA

420 Stevens Avenue, Suite 170 Solana Beach, CA 92075

#### **Boston, MA**

35 Cambridgepark Drive, Suite 150 Cambridge, MA 02140

